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Abstract 
Thirty-three 1,4-dihydropyridine diastereomeric pairs were synthesized and the structure-
activity relationship studied in a Plasmodium falciparum in vitro model. Twenty-nine of 
these derivatives contained a 6-position oxygen, with 2.31, 2.32, 2.52 and 2.53 having 
single and double digit nanomolar activities. This SAR study revealed some insightful 
information about the 1,4-dihydropyridine substitution pattern. Substitution at the 7-
position other than 3,4-dimethoxy severely reduced the activity. 4-phenyl substitution 
with 2- or 4- halo or methyl formed active compounds while substitution at the 3-position 
or with methoxy or conjugated aryl systems resulted in inactive compounds. The 2-
position was found to majorly affect the activity, with groups larger than methyl being 
the most active. The other four derivatives contained a 6-position methylene, with 2.1, 
2.59 and 2.60 having single nanomolar activities. Lastly, stereochemistry was revealed to 
play an important role in the activity of 2.1. One stereoisomer, (+)-trans-2.1, had 
subnanomolar activity in two assays. Another stereoisomer, (4S,7S)-2.1, had nanomolar 
activity. The other two stereoisomers were inactive. 
A series of N
2
,N
4
-disubstituted quinazoline-2,4-diamines has been synthesized and tested 
against Leishmania donovani and Leishmania amazonensis intracellular amastigotes. A 
structure-activity and structure-property relationship study was conducted in part using 
the Topliss operational scheme to identify new lead compounds. This study led to the 
identification of quinazolines with EC50s in the single digit micromolar or high 
nanomolar range in addition to favorable physicochemical properties. Quinazoline 3.23 
xx 
 
also displayed efficacy in a murine model of visceral leishmaniasis, reducing liver 
parasitemia by 37% when given by the intraperitoneal route at 15 mg/kg/day for five 
consecutive days. Their antileishmanial efficacy, ease of synthesis, and favorable 
physicochemical properties make the N
2
,N
4
-disubstituted quinazoline-2,4-diamine 
compound series a suitable platform for future development of antileishmanial agents. 
A similar series of N
2
,N
4
-disubstituted quinazoline-2,4-diamines has been synthesized 
and tested against methicilin-resistant Staphylococcus aureus (MRSA) and multi-drug 
resistant strains of Acinetobacter baumannii. Quinazolines with MICs in the single digit 
micromolar or high nanomolar range were identified via SAR. In a murine model of 
MRSA infection, 1x the MIC for quinazoline 4.47 allowed for the survival of all tested 
mice at the end of a one week study. An in vivo model of A. baumannii was also 
undertaken using a Galleria mellonella model of infection. Quinazolines 4.68, 4.70 and 
4.71 afforded an increased protection of 87.5% when compared to the control 
experiments, with 70% of the wax worms surviving until day three. The observed 
potencies of frontrunner compounds in in vivo assays and their ease of synthesis make 
N
2
,N
4
-disubstituted quinazoline-2,4-diamines a suitable platform for the future 
development of anti-bacterial agents. 
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Chapter 1: Introduction to Anti-microbials 
1.1 Overview 
Microorganisms, or microbes, are microscopic organisms that are found all over the 
world. Microbes may be prokaryotic or eukaryotic, multicellular or unicellular. This 
diverse group of organisms has played a huge role in the ecology of Earth. Bacteria 
participate in the nitrogen cycle in the process of nitrogen fixation to turn inorganic 
nitrogen gas to usable ammonium and nitrate. Algae and cyanobacteria perform 
photosynthesis to turn carbon dioxide into sugars and oxygen. There is also the fact that 
all life on earth evolved from these organisms. Microorganisms also play a more local 
role in mammalian life. Bacteria within the digestive tract play a pivotal role in the health 
of the human body. The treatment of sewage is undertaken with the help of a panoply of 
microorganisms. The synthesis of many and large amounts of antibiotics such as 
penicillin are only undertaken with the use of bacteria. Most important, a great pastime of 
food and drink could not be undertaken without the help of yeast.
1
 
Although microorganisms are known to be productive members of this planet, oftentimes 
they also prey on other life forms. Eukaryotes, such as the tropical disease causing 
parasites of the genera Leishmania and Plasmodium, and prokaryotes, such as the 
infection causing bacteria of the genera Acinetobacter and Staphylococcus, both are 
causes of human infection. Eukaryotic and prokaryotic cells can be mobile or immobile. 
In the case of the aforementioned bacteria, immobility is the way of life. The eukaryotic 
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Leishmania and Plasmodium, on the other hand, both display periods of mobility in their 
life cycles. Leishmania promastigotes have a flagellum for movement which they lose 
upon transforming to amastigotes.
2
 Plasmodium sporozoites are able to travel via gliding, 
a mechanism characterized by the lack of any cell modification during movement.
3
 These 
four human pathogens will be studied in more depth within the coming sections. 
1.2 Protozoa 
1.2.1 Genus Plasmodium 
Malaria is a parasitic disease with half of the world’s population living in affected areas.4 
Although only fifteen hundred cases of malaria are reported in the United States annually, 
nearly one million people die worldwide each year from malaria and an additional two 
hundred million are infected.
4
 These fatalities make malaria the fifth highest worldwide 
cause of death following respiratory infections, HIV/AIDS, diarrheal diseases and 
tuberculosis.
4b
 Thirty five countries, thirty in sub-Saharan Africa and five in Asia, 
account for 98% of the annual fatalities, while sub-Saharan Africa alone accounts for 
89%.
4b
  
Malaria is a disease that is caused in humans by protozoan parasites of the genus 
Plasmodium. Five species have been found to cause malaria in humans: P. falciparum, P. 
vivax, P. ovale, P. malariae, and P. knowlesi. P. falciparum and P. vivax are the two most 
commonly found although P. falciparum is by far the most deadly with nearly all fatal 
and severe cases of malaria, resulting from the large population of parasites which grow 
inside of an infected individual.
5
 The parasites are transmitted by a mosquito vector of 
the genus Anopheles, whereby a mosquito ingests a blood meal from an infected 
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individual and the transmission occurs when the mosquito next takes a blood meal and 
expels the parasites into the new host.
4
 The World Health Organization estimates that 219 
million people were infected by malaria and that 660,000 people died worldwide due to 
malaria in 2010.
6
 One of the major reasons for such a large population of people being 
affected by this disease is that it is definitely increased in impoverished areas. Poorer 
populations have a higher chance of getting malaria as they tend to live in rural areas, do 
not have proper protection in place to reduce contact with mosquitoes and do not have 
access to health facilities which may help them to prevent or cure the infections.
6
 80% of 
the cases and 91% of the deaths were accounted for by sub-Saharan Africa. Along with 
this figure, 86% of the deaths were children <5 years old.
6
  
The parasites are spread by the bite of approximately twenty species of mosquitoes in the 
genus Anopheles.
4
 When an infected female mosquito bites an animal for a blood meal, 
Plasmodium sporozoites are injected into the epithelial cells. These sporozoites migrate 
through the body until they end up in hepatocytes in the liver of the infected individual 
(Figure 1.1).
4
 Here the sporozoites mature by replicating organelles and the nucleus and 
become a schizont, which then divides cellularly to become merozoites. The merozoites 
are then released to the rest of the body when the hepatocyte ruptures after a period of 
seven days to several weeks, depending on the species.
4
 The newly released tens of 
thousands of merozoites infect erythrocytes in the blood stream where they become 
schizonts and asexually reproduce until the cells burst, restarting the erythrocyte 
infection.
4
 A small number of merozoites transform into male and female gametocytes, a 
sexual form of the parasite that may infect an uninfected Anopheles mosquito when it 
takes a blood meal from the infected animal.
4b, 5
 In P. falciparum the gametocytes form 
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later on, with health of the host deteriorating prior to transmission. In P. vivax, however, 
gametocytes form much earlier and may be transmitted prior to any clinical manifestation 
of the disease.
7
 
Inside the stomach of the mosquito, a male gamete combines with a female gamete to 
form a zygote. The zygote transforms into a mobile ookinete which enters the stomach 
lining and grows into a non-mobile oocyst. This oocyst is thick-walled and multiplies 
until sporozoites burst from the cell. The sporozoites migrate to the salivary glands of the 
mosquito and from here they are injected to a new host when the mosquito takes another 
blood meal.
4
  
 
Figure 1.1: The malaria parasite life cycle
4b
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As merozoites leave the liver and infect the rest of the body, signs of infection appear. 
With the asexual replication of the merozoites in the erythrocytes, toxins are released 
which harm the host.
5
 Flu like symptoms, fever, headache, chills and vomiting are the 
first symptoms observed in people who are infected with malaria. Severe symptoms that 
may develop include impaired consciousness, coma, prostration, acidosis, respiratory 
distress, organ dysfunction including jaundice, hypoglycemia, renal failure, anemia and 
abnormal bleeding.
5
 Early identification of the disease reduces the fatality of the severe 
symptoms. 
1.2.1.1 Anti-Malarials 
Through the years, a number of drugs have been used to treat malaria. The cinchona 
alkaloids, including quinine, may have been the first with the use of teas and extracts 
from the cinchona bark during the last few centuries in South America and Europe.
8
 The 
cinchona alkaloids, cinchonine, cinchonidine, quinine and quinidine, all display anti-
malarial properties but quinine became the alkaloid that moved forward because of a 
higher amount present in the natural resource.
8
 The use of quinine waned with the onset 
of new anti-malarials, including chloroquine. In recent years, quinine has returned as a 
second-line treatment in combination therapy to reduce the incidence of resistance. 
Chloroquine was introduced for clinical use in 1947 and has since then been used as a 
staple for treatment and prevention of malaria (Figure 1.2). As a 4-aminoquinoline, 
chloroquine’s mechanism of action involves the disruption of the formation of hemozoin, 
a crystalline polymer made from the byproduct of hemoglobin consumption by the 
parasite.
9
 A chloroquine-heme complex is incorporated within the polymer, capping and 
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preventing the elongation of the crystal within the parasite lysosomal food vacuole.
9
 This 
capping of the polymer allows the heme to build up in the parasite, leading to cell death 
most likely via oxidative damage and disruption of the cell membrane.
9
 Chloroquine 
resistance was first seen in the 1950’s and can be caused by an efflux mechanism.10 The 
PfCRT protein is an efflux protein located in the food vacuole membrane and is a cause 
for chloroquine resistance as it actively removes quinoline molecules from the 
organelle.
10c, d
  
Pyrimethamine is a 2,4-diaminopyrimidine that began clinical use in 1953 (Figure 1.2). It 
is given in combination with the sulfonamide sulfadoxine. Pyrimethamine is a 
dihydrofolate reductase (DHFR) inhibitor and sulfadoxine is a dihydropteroate synthase 
(DHPS) inhibitor and in combination are effective inhibitors of the synthesis of 
tetrahydrofolate, a cofactor for thymidilate, purine nucleotides and certain amino acid 
synthesis.
11
 Resistance is encountered when DHFR and/or DHPS mutations occur that 
result in reduced binding and inhibition by each drug.
11
 
Mefloquine is a quinoline derivative quite similar to quinine that was developed in the 
1960’s by the Division of Experimental Therapeutics at Walter Reed Army Institute of 
Research (WRAIR) and approved for use by the FDA in 1989 (Figure 1.2).
12
 Resistance 
was first seen in Southeast Asia and it is no longer an effective treatment in certain 
areas.
11c, 12-13
 Halofantrine is a phenanthrene that, like mefloquine, was created in the 
1960’s at WRAIR and FDA approved in 1992. It was initially used in areas with 
mefloquine resistance; however, it was found that it was much less effective in these 
areas.
11c, 12
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Atovaquone is a naphthoquinone that began clinical use in 1992 (Figure 1.2). 
Atovaquone interrupts the electron transport chain in the cytochrome bc1 complex of 
mitochondria which blocks the biosynthesis of pyrimidine and it also collapses the 
electropotential across the mitochondrial membrane, resulting in parasite death.
12, 14
 
Atovaquone is generally given in combination therapy with proguanil, a DHFR inhibitor, 
as atovaquone resistance generally occurs readily when given on its own.
12, 14
 Resistance 
has been seen via a mutation in the gene coding for the cytochrome bc1 complex.
14-15
 
In the late 1960’s the Chinese government invested heavily in finding anti-malarial 
compounds. In 1971 the natural product artemisinin was discovered to have potent anti-
malarial properties through the help of ancient medicinal texts (Figure 1.2).
16
 In the early 
1980’s this great discovery was shared with the rest of the world. A few derivatives of 
artemisinin were found to have better properties and activity including 
dihydroartemisinin (DHA), artemether and artesunate.
16-17
 These derivatives are given in 
combination known as artemisinin-based combination therapies (ACTs) as first line 
treatments. Resistance to the artemisinins are hoped to be reduced this way and extend 
the life of the ACTs. Current ACTs in use include artemether with lumefantrine, 
dihydroartemisinin with piperaquine, and artesunate with either amodiaquine, mefloquine 
or sulfadoxine-pyrimethamine.
17-18
 In 2006 artemisinin resistance was reported in 
Southeast Asia and ACT resistance has been noted with artesunate-mefloquine in this 
region.
18-19
 ACTs are currently the most relied on anti-malarial in use and resistance to 
these combinations will be highly detrimental to many countries. 
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P. ovale and P. vivax often cause relapse in patients months or years after they are 
clinically cured of malaria. These two species form hypnozoites in the liver, a form of the 
parasite that is dormant and unaffected by the previously shown drugs which generally 
kill the erythrocytic stage of the parasites.
20
 Primaquine is an 8-aminoquinoline that was 
first used in World War II and is able to kill these dormant parasites (Figure 1.2). It is 
currently used primarily as a relapse preventer in cases of P. ovale and P. vivax in 
combination with drugs that kill blood stage parasites.
12, 20
 
Although many drugs are available to treat malaria, many are largely cost prohibitive and 
this makes their use in poor endemic areas where malaria is present a large financial 
burden. Current research is aimed at the production of less expensive, one time drugs that 
will allow for cost effectiveness and non-extended periods of drug therapy. 
1.2.2 Genus Leishmania 
Leishmaniasis is a debilitating disease that is prevalent across the globe. More than 
twenty species of parasite in the genus Leishmania are known to cause the disease in 
humans.
21
 The parasites are transferred from host to host by about thirty species of 
female sandfly vectors of the genera Phlebotomus and Lutzomyia that infect the host with 
promastigotes when taking a blood meal (Figure 1.3).
22
 The flagella containing 
promastigotes infect the macrophages of the mammalian host, where the flagellum is lost 
and the promastigote becomes an amastigote. The amastigotes multiply within the 
macrophages, increasing the parasite burden on the host and infecting new cells when the 
macrophage bursts. Infected macrophages are ingested by a sandfly when a bloodmeal is 
taken, resulting in a new infected vector that can transmit the disease to a new host. 
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Figure 1.2: Structures of anti-malarials 
Symptoms of leishmaniasis include unsightly spontaneously healing ulcers on the skin 
when cutaneous leishmaniasis presents, non-healing lesions in the mucosa when 
mucocutaneous leishmaniasis is the affliction, and chronic, debilitating infection of the 
reticuloendothelial system which is fatal if left untreated due to visceral leishmaniasis. 
23
 
The majority of cases of visceral leishmaniasis, also known as kala-azar, are caused by L. 
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donovani in East Africa and Asia, L. infantum in the Mediterranean region, and L. 
chagasi in Latin America.
21
 L. infantum and L. chagasi mainly affect children and 
immunocompromised individuals and are zoonotic parasites with canines being a major 
reservoir.
23
 L. donovani, on the other hand, is an anthroponotic parasite and affects a 
broad range of ages.
23
 Throughout the world, 350 million people in 88 countries are at 
risk of acquiring leishmaniasis.
24
 The World Health Organization (WHO) estimates that 
1-1.5 million people acquire cutaneous leishmaniasis and five hundred thousand others 
are afflicted with visceral leishmaniasis annually, with over 50,000 deaths per year.
22, 24
  
 
Figure 1.3: Life cycle of the Leishmania parasite 
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1.2.2.1 Anti-leishmanials 
For over one hundred years, antimonials have been the drug of choice to combat 
leishmaniasis. In 1912, Gaspar Vianna first reported the use of the trivalent antimonial 
tartar emetic for the treatment of cutaneous leishmaniasis caused by L. braziliensis in 
Brazil.
25
 Pentavalent antimonials such as meglumine antimoniate and sodium 
stibogluconate are currently the first line drugs for treatment in many areas (Figure 
1.4).
23, 26
 Treatment involves daily injections for up to a thirty day period.
8
 Problems of 
using this treatment includes a high rate of resistance that has been encountered in India, 
especially the state of Bihar, where up to 60% of infected individuals do not improve 
with treatment.
26a, 27
 Since the 1960’s, amphotericin B has been the second line of 
treatment for visceral leishmaniasis.
8
 It has a cure rate of over ninety percent, but is often 
accompanied by severe side effects such as nephrotoxicity that require administration in a 
hospital setting.
26a, 28
 Depending on the dose and formulation, the treatment regimen 
varies from 3-5 days to eight weeks of administration on alternate days.
21, 26a
 Miltefosine 
is the first oral drug to be released for leishmaniasis and is currently available in India, 
Germany, and Colombia.
8
 Miltefosine is not recommended for women who are pregnant 
or may become pregnant because it is teratogenic.
23, 26a
 Miltefosine resistance has been 
demonstrated in vitro, and its long half-life in the body, the twenty-eight day treatment 
regimen, as well as it previously being available over the counter in India leads to 
concerns of clinical resistance.
23, 26a, 29
  A recent study of 567 individuals in the Bihar 
state of India has been performed to determine the efficacy of miltefosine since its 
induction in 2002.
30
 The six month cure rate was found to be roughly 90% and 
gastrointestinal intolerance was encountered in 64.5% of the cases with two deaths 
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related to drug toxicity.
30
 Patients who did not improve with treatment were cured using 
amphotericin B. The authors of this study concluded that the failure rate of miltefosine 
has increased in the ten years since its introduction for the treatment of visceral 
leishmaniasis in India. 
 
Figure 1.4: Common anti-leishmanials 
1.3 ESKAPE Pathogens 
Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter species make up an infamous 
group of bacteria known as the ESKAPE pathogens. These microbes are of import due to 
resistance to common anti-bacterials and the fact that they are often hospital acquired 
13 
 
infections (HAIs).
31
 Both Gram-positive and Gram-negative bacteria are found in the 
ESKAPE pathogens. Most bacteria form a cell well outside of their plasma membrane 
and the make-up of this cell wall is what determines whether they are Gram-positive or 
negative (Figure 1.5).
1
  
 
Figure 1.5: Cell wall of a Gram-positive and a Gram-negative bacterium 
Peptidoglycan is a polymer of sugar cross-linked by short polypeptides and is found in 
bacterial cell walls. Gram-positive bacteria have a comparatively large amount of 
peptidoglycan and are less complex.
1
 The higher complexity in Gram-negative bacteria is 
due to a lipid membrane outside the peptidoglycan that contains anionic 
lipopolysaccharides.
1
 These lipopolysaccharides can be toxic and the outer membrane 
creates an extra barrier that protects from host attacks and increases the difficulty for 
antibiotics, especially the hydrophobic variety, to enter the cell.
1
 Many antibiotics inhibit 
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the cross-linking of peptidoglycan and because of the smaller amount of peptidoglycan 
and the presence of an outer membrane they will not affect Gram-negative species as 
well. 
1.3.1 Staphylococcus aureus 
Bacteria of the genus Staphylococcus are Gram-positive facultative anaerobes with a 0.5 
to 1 m diameter that form clusters like grapes.32 These bacteria are pathogens of 
mammals, including man, and cause infections of the skin, urinary tract, blood and 
respiratory system among others. 
S. aureus is the leading cause of staphylococcal infection in humans. It is estimated that 
20% of the world population are persistent carriers of this species in the nasal cavity and 
axillae while 60% of the population are intermittent carriers.
32-33
 In the United States the 
population of carriers is around 30%.
34
 S. aureus is frequently found as a nosocomial 
infection (HAI), with numerous infections being encountered from hospital stays and 
long term healthcare facilities every year. This bacterium causes a wide range of 
infections, from minor skin infections such as pimples, impetigo, boils and other 
abscesses to severe infections including osteomyelitis, pneumonia, meningitis, toxic 
shock syndrome, phlebitis, mastitis and endocarditis. The severe infections are often seen 
by hospital patients if they become infected during their stay. Community-acquired 
infections (CA-MRSA) are caused by strains of S. aureus that are distinct from the 
hospital acquired strains. Whereas the HAIs are opportunistic of unhealthy, 
immunocompromised people, CA-MRSA infections can be found in typically healthy 
hosts with no risk factors. CA-MRSA infections are oftentimes overwhelming, tissue 
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destructive infections such as necrotizing fasciitis and fulminant, necrotizing 
pneumonia.
35
  
1.3.1.1 Staphylococcal Toxins 
Numerous toxins and proteins are released by S. aureus and are the root of disease in a 
host. These proteins include enzymes such as nucleases, proteases, collagenase, 
hyaluronidase and lipases and the toxins that can be found are alpha-, beta-, gamma- and 
delta- hemolysins, toxic shock syndrome toxin-1 (TSST-1), staphylococcal enterotoxins 
(SEs), exfoliative toxins and Panton-Valentine leukocidin, most of which are released in 
the post exponential growth phase.
36
 At this point of growth the bacteria have divided 
until the amount of nutrients has reduced. Many of the toxins are believed to diminish the 
immune response of the host and the proteins break down tissues into nutrients for 
bacterial growth.  
The staphylococcal enterotoxins and TSST-1 fall into a category of toxins known as 
pyrogenic toxin superantigens (PTSAgs). The PTSAg class of toxins display at least three 
properties: pyrogenicity, superantigenicity and the ability to increase the lethality of 
endotoxin in rabbits up to 100,000 fold.
36-37
 Staphylococcal enterotoxins are also potent 
emetic agents whereas TSST-1 can cross mucosal surfaces and reactivate bacterial cell 
wall-induced arthritis.
38
 The genes for the PTSAgs are stored in pathogenicity islands 
such as plasmids, bactereophages and heterologous genetic fragments.
39
 The mature 
PTSAg has a molecular weight between 20 and 30 kiloDaltons (kDa) when released from 
the cell and is a nonglycosilated polypeptide. The PTSAg toxins are found in people 
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having menstrual (TSST-1) and nonmenstrual (SEs) toxic shock syndrome, sudden infant 
death syndrome, food poisoning and Kawasaki syndrome.
36
 
 
Figure 1.6: Crystal structure of alpha-hemolysin
40
 
Alpha-hemolysin is a pore forming toxin that is found in numerous strains of S. aureus 
and because of this is one of the most studied toxins produced.
36
 The mature polypeptide 
has a mass of 33 kDa and is composed of 65% -sheets and 10% -helices (Figure 1.6). 
It is formed in the cell during the late exponential phase of cell growth. When released 
from the cell, alpha-hemolysin incorporates into host cells as oligomers, forming 1-2 nm 
pores in the cell membranes as heptamers that may cause the eukaryotic cells to lyse.
36, 41
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This pore allows efflux of K
+
 and influx of Na
+
, Ca
2+
 and small molecules less than 1 
kDa, resulting in rupture of the cell due to osmotic swelling.
36, 42
  Alpha-hemolysin is 
able to affect numerous cells including epithelial cells, erythrocytes, fibroblasts and 
monocytes.
36, 42
 
β-Hemolysin is formed by a large number of S. aureus strains, but its role in disease is 
not known. Gamma-hemolysin and Panton-Valentine leukocydin (PVL), however, are 
known well as affecting mammalian cells and causing disease.
36
 PVL is made in less than 
5% of strains while gamma-hemolysin is synthesized in nearly every strain. These toxins 
are similar in that they are composed of two protein subunits and affect neutrophils and 
macrophages. PVL forms pores in host leukocytes, and at high concentration will cause 
lytic cell death. At lower concentrations it will activate neutrophils to release granule 
contents via exocytosis and secrete leukotrine B4 and interleukin 8 which causes 
inflammation.
35d, 36, 43
 PVL is thought to be a major cause of the virulency and tissue 
destruction found in CA-MRSA.
44
  
Delta-hemolysin is a 3 kDa peptide that also causes membrane damage and cell lysis. It is 
believed that delta-hemolysin acts as a surfactant in cell membranes with the release of 
larger molecules as longer exposure time to the toxin is experienced. This toxin is able to 
lyse erythrocytes and other cells as well as internal organelles.
36
 
1.3.1.2 Antibiotics for Staphylococcus aureus 
Alexander Fleming’s remarkable discovery of Penicillin in 1928 and the following work 
by Florey, Chain and coworkers of its isolation led to a revolution in modern day 
medicine.
45
 Previously fatal infections were curable by a simple infusion of this new 
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antibiotic. It wasn’t until late 1942 and early 1943 that the new drug was mass produced, 
with the British and American governments recognizing the use of antibiotics in the war 
effort. In 1940 Abraham and Chain first identified and named penicillinase, a source of 
penicillin resistance in S. aureus.
46
 Shortly thereafter penicillin resistant infections were 
encountered in hospitals.
35d, 47
 
The penicillins are a group of antibiotics that are secondary metabolites of certain species 
of the fungi in the genus Penicillium. The major features of the penicillins are the β-
lactam and thiazolidine fused rings (Figure 1.8). β-Lactams inhibit the penicillin-binding 
proteins (PBPs) that are necessary for peptioglycan biosynthesis.
45
 Penicillinase 
hydrolyzes the β-lactam ring of the penicillins, causing deactivation (Figure 1.7). The 
gene coding for penicillinase was found in a plasmid within the resistant bacteria.
35d
  
 
Figure 1.7: β-Lactam deactivation by penicillinase 
The late 1940’s and early 1950’s brought the discovery of cephalosporin C, a β-lactam 
fused to a dihydrothiazine ring that was inactive to the penicillinase that hampered the 
penicillins (Figure 1.8). The activity of this compound was much lower than the 
penicillins and it wasn’t until analogues were made in the 1960’s that the cephalosporins 
made headway as antibiotics.
45
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In the late 1950’s after penicillin resistance was a major factor, the Beecham Research 
Laboratories made semi-synthetic penicillin analogues that stemmed from 6-
aminopenicillanic acid (6-APA) (Figure 1.8). The idea was to add bulky side chains to 
the amide functional group in order to prevent the β-lactamase enzyme from opening the 
β-lactam that caused the penicillins to be ineffective. In 1959 they made methicillin, 6-
amino-N
6
-(2,6-dimethoxybenzoyl)penicillanic acid, which remained an effective 
antibiotic in the presence of penicillinase.
45
 Cloxacillin, oxacillin, flucloxacillan and 
dicloxacillan were similar analogues that displayed better blood concentrations in vivo. 
Ampicillin, a penicillin derivative bearing a benzyl amine residue, was released in 1961 
and is of some import as it was one of the first broad spectrum antibiotics, with antibiotic 
effects in gram negative bacteria, even though it was still hydrolyzed by β-lactamases. 
Amoxicillin is an analogue of ampicillin bearing a phenol that increases the oral-
bioavailability of the β-lactam and was released in 1972.48 
In 1959, methicillin was released as a S. aureus killer that was unaffected by β-lactamase. 
In 1961, however, the first strains of methicillin resistant Staphylococcus aureus (MRSA) 
were encountered.
35d, 49
 Unlike the β-lactamase deactivation, hydrolysis of the β-lactam 
ring did not occur and resistance to methicillin conferred resistance to all β-lactams.45, 50 
The new strains made a new penicillin binding protein, PBP2a, that was encoded by the 
mecA gene and had low affinity to β-lactams. PBPs cross link peptidoglycan chains in the 
cell wall and the new membrane-bound protein is unaffected by high concentrations of all 
β-lactams.51  
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In the early to mid-1950’s Eli Lilly isolated a glycopeptide from a soil sample containing 
bacterial growth. This glycopeptide was vancomycin, a polypeptide that displayed 
activity against Gram-positive bacteria (Figure 1.8).
48
 Due to poor bioavailability and 
side effects, vancomycin was not used as a first treatment option, especially with the 
advent of non-penicillin antibiotics. This, combined with the low resistance from 
susceptible bacteria, has allowed for vancomycin to be a last resort for bacterial 
infections since its FDA approval in 1958.
48
 Teicoplanin is another glycopeptide that has 
similar use to vancomycin. The glycopeptides interrupt cell wall synthesis by blocking 
cross linking between peptidoglycan.
45
 Due to increased multi-drug resistance across 
bacterial strains, glycopeptides have been used at a much higher rate in the last 25 years, 
resulting in the first report of vancomycin intermediate-resistant S. aurues (VISA/GISA) 
in 1997 from a MRSA strain in Japan.
52
 Since then, VISA and vancomycin resistant S. 
aureus (VRSA) have become more prevalent across the globe.
53
 VRSA isolates have 
been found to contain the vanA operon from vancomycin resistant Enterococcus faecalis 
(VRE), showing that resistance has been transferred via plasmid between orders.
51
  
Broad spectrum fluoroquinolones, such as ciprofloxacin, were introduced in the mid 
1980’s (Figure 1.8). Fluoroquinolones act by inhibiting two enzymes that unwind 
bacterial DNA, DNA gyrase and topoisomerase IV.
45, 51
 By 1990 mild resistance was 
seen via efflux with an over expression of the multidrug NorA pump.
45, 51
 Nucleic acid 
mutations have also resulted in amino acid substitution in the target enzymes that reduced 
the binding affinity of the quinolones.
51
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Figure 1.8: Structure of early antibiotics 
The ability of bacteria to acquire resistance to so many drugs is multifold. The multitude 
of bacteria present in an infection allows for chromosomal mutations that create 
numerous phenotypes that may through randomization create a bacterium that is not 
susceptible to a specific antibiotic. When bacteria are part of the normal fauna, as in the 
20% of human population who are persistent carriers of S. aureus in the nasal cavities, 
antibiotics that are used to treat bacterial or viral infections may affect the fauna in lower 
than therapeutic doses, creating an environment with the high potential for resistance.
51
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Improper use of antibiotics, such as a patient not finishing a prescription or the improper 
prescribing of antibiotics for viral infections, has also played a part in resistance. Once 
resistance has been found in any species of bacteria, it is possible for that resistance to be 
transferred via plasmid or bacteriophage, as is the belief with VRE transfer to VRSA.
51, 53
 
One last cause of resistance may be the ability for bacteria to from biofilms. Biofilms are 
a type of bacterial growth where aggregates come together and form a layer on surfaces 
that allows for protection during growth in hostile environments.
54
 The formation of 
biofilms give bacteria an inherent resistance to any attack, be it from a host immune 
system, amoeba or antibiotics. Attempts to combat an infection caused by a biofilm will 
increase the chance that cells in the biofilm will grow resistance to the antibiotic in use, 
since a lower concentration of drug will affect each cell. 
Quinupristin and dalfopristin are two semisynthetic pristinamycins that are used in 
combination and are active against MRSA and VRSA strains and FDA approved in 1999 
(Figure 1.9).
55
 The combination works by inhibiting cytochrome P450 and prevents the 
synthesis of important biochemical molecules. Resistance has been seen via efflux 
mechanisms and mutation of the enzyme.
55-56
  
Linezolid is an oxazolidinone that is active against Gram-positive bacteria and was 
approved for use by the FDA in 2000 (Figure 1.9). Linezolid works by preventing protein 
synthesis via binding the ribosomal 23S rRNA at doman V and preventing binding of the 
initiator fMet-tRNA.
57
 Although serious adverse affects can be encountered, linezolid can 
be substituted for vancomycin which also has serious side effects. In 2001 the first 
clinical isolates were found bearing linezolid resistance.
58
 Resistance has been found 
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from a few mechanisms, including point amino acid mutations and methylation of the 
23S rRNA by a horizontally transferred methyltransferase encoded by the plasmid 
encoded crf gene.
57a, 59
  
Daptomycin is a cyclic lipopeptide that was FDA approved in 2003 (Figure 1.9). It kills 
bacteria by disrupting membrane depolarization by insertion into the cell membrane 
resulting in the release of potassium ions and the cessation of biochemical functions in 
the cell.
60
 By 2005 resistance had been encountered.
61
  
In 2005 the FDA approved the broad spectrum tetracycline drug tigecycline for use 
against Gram-postive and Gram-negative bacteria (Figure 1.9). This compound is of note 
as tetracycline resistance has long been shown in Gram-positive and Gram-negative 
bacteria.
62
 Tetracycline resistance is conferred by ribosomal protections and efflux 
mechanisms and it is believed that tigecycline is able to overcome this due to a bulky 
substituent on the 9-position, although activity is mildly reduced in the presence of 
multidrug efflux pumps.
62-63
 The mechanism of action of tigecycline is the binding of the 
30S ribosomal subunit, causing the inhibition of protein synthesis.
62
 
Telavancin, a semi-synthetic lipoglycopeptide, was FDA approved in 2009 (Figure 1.9). 
Telavancin has the same mechanism of action as other glycopeptides, but still displays 
activity against vancomycin resistant strains, although the activity is less than that for 
MRSA strains.
55, 64
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Figure 1.9: MRSA anti-bacterial drugs approved by the FDA since 1999 
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Ceftaroline fosamil is a broad-spectrum cephalosporin that was FDA approved in 2010 
(Figure 1.9). Ceftaroline has a mechanism of action similar to other β-lactams wherein it 
binds to PBPs, including PBP2a which caused resistance among β-lactams following 
methicillin resistance in the 1960’s.65 It is also active against vancomycin resistant strains 
of S. aureus and is generally prescribed for infections associated with CA-MRSA, 
including pneumonia and severe skin infections.  
Ceftobioprole is another cephalosporin that is also active against MRSA and VRSA 
strains but has not gained FDA approval.
66
 Dalbavancin is also awaiting FDA approval 
and is a lipoglycopeptide that is active against MRSA but not against VRSA strains.
55
 
Another glycopeptide is the semi-synthetic oritavancin that displays activity against 
MRSA and VRSA strains. Clinical trials are being repeated for this compound.
55
  
 
1.3.2 Acinetobacter baumannii  
Acinetobacter is a genus of Gram-negative coccobacilli bacteria that is strictly aerobic, 
catalase positive and oxidase negative.
67
 Bacteria of this genus can be found in water, 
soil, and as normal fauna of animals, including human skin.
68
  
A. baumannii is a cause of infection in the human populace. It has few virulence factors 
with most infections in immunocompromised persons.
67a, 68-69
 Most infections 
encountered include nosocomial pneumonia, meningitis, urinary tract infections, wound 
infections such as surgical site infections, and bloodstream infections from central line 
infections.
68
 People who are at risk for A. baumannii infections are those who are elderly, 
are immunocompromised, have had invasive procedures, have catheters, use mechanical 
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ventilation and those who have had major trauma, especially burn victims.
67a
 One reason 
for the high rate of manifestations in the hospital is that A. baumannii is able to survive 
long periods of time in a dry environment, meaning that contaminated surfaces may leave 
viable bacteria for several months.
67a, 69-70
 
Along with the lipopolysaccharide of the outer membrane, one of the known virulence 
factors in A. baumannii is the outer membrane protein 38 (Omp38, also known as 
OmpA), a 38 kDa porin.
71
 Omp38 has been found to localize at the mitochondria of 
epithelial cells causing mitochondrial release of apoptosis inducing factor (AIF) and 
cytochrome c and resulting in apoptosis of the eukaryotes.
71
  
1.3.2.1 Antibiotics for Acinetobacter baumannii 
Since the early 1970’s, nosocomial infections of A. baumannii have shown antibiotic 
resistance to compounds that it was previously susceptible such as gentamicin, 
minocycline, ampicillin, carbenicillin, chloramphenicol and nalidixic acid.
72
 Sulbactam 
and group 2 carbapenems have been the drugs of choice for multidrug resistance 
strains.
67a
 In the mid 1980’s a gene was found that encodes a carbapenem-hydrolyzing 
class D -lactamase (CHDL or carbapenemase), called OXA-23.73 This enzyme is 
transferred via plasmid but can be found within the chromosome and is known to 
hydrolyze penicillins and some cephalosporins as well.
73
 This enzyme and its variants are 
not very effective, but upregulation of the gene may occur resulting in resistance.
67a, 74
 On 
its own or in collaboration with CHDLs, carbapenem resistance has also been seen by 
loss of certain outer-membrane proteins that facilitate the influx of these -lactams.74 The 
study of a French strain of A. baumannii has revealed the presence of resistance genes 
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transferred from numerous other bacteria.
75
 AbaR1, an 86 kb resistance island, was found 
to have 88 open reading frames that came from other organisms, 39 from Pseudomonas 
spp., 30 from Salmonella spp. and 15 from Eschericia coli.
75
 45 resistance genes were 
found within the AbaR1 resistance island.
75
  
Carbapenems that are used as common treatments include imipenem and meropenem 
(Figure 1.10). Imipenem, approved in 1985, is usually given as combination therapy with 
cilastitin, an inhibitor of dehydropeptidase I that hydrolyzes imipenem.
76
 Meropenem was 
released in 1996 and is not susceptible to this hydrolysis. The mechanism of action for 
carbapenems is the same as for other -lactams, but in Gram-negative bacteria the 
antibiotic enters the periplasmic space between the cell wall and outer cell membrane via 
porins.
76
  
Colistin is a polymyxin that became available for clinical use in 1959 (Figure 1.10). Its 
use prior to recent years has been minimal due to nephrotoxicity and neurotoxicity side 
effects.
77
 Polymyxins are cyclic polyamine peptides with a fatty acid side chain that 
disrupt the cell membrane by the interaction of the many primary ammonium 
functionalities with the anionic lipopolysaccharide on the outer membrane of Gram-
negative bacteria.
78
 The displacement of Mg
2+
 and Ca
2+
 that form salt bridges between 
the lipopolysaccharide reduces the stability of the membrane, along with the insertion of 
the fatty acid side chain into the hydrophibic lipid layer, resulting in the escape of 
intracellular components and finally cell death.
67a, 78
 Resistance to polymyxins has been 
observed and the mechanism is thought to be a change in the outer membrane with the 
possible reduction of lipopolysaccharides.
77
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Tigecycline has shown promising results against multidrug resistant A. baumannii, 
although it has a low blood serum concentration resulting in poor efficacy against 
bloodstream infections.
62, 67a
 Tigecycline is also a poor candidate for the treatment of 
urinary tract infections as it is not cleared from the body by the kidneys.
67a
 A few cases 
have been reported of tigecycline resistance occurring during therapy for these types of A. 
baumannii infections.
79
 
 
Figure 1.10: Gram-negative antibiotics active against Acinetobacter baumannii 
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Chapter 2: 1,4-Dihydropyridines as Anti-Malarials 
2.1 Hantzsch Pyridine Synthesis 
The Hantzsch pyridine synthesis is an old reaction that still has applicability in today’s 
chemistry.
80
 Classical Hantzsch syntheses employ two equivalents of β-ketoesters with 
one equivalent of amine and aldehyde to form the symmetrical 1,4-dihydropyridine 
derivatives (Figure 2.1). This reaction, from the late 19
th
 century, is still used as a reliable 
method for forming an assortment of 1,4-dihydropyridine products. Asymmetric 
compounds may be made by using two different β-ketoesters or one β-ketoester with a β-
diketone compounds. 
 
Figure 2.1: Classical Hantzsch pyridine synthesis 
This 1,4-dihydropyridine system has six  electrons delocalized over 5 atoms of the 
pyridine ring, and this delocalization is extended to the carbonyls at the 3- and 5- 
positions as well. 
81
 The oxidation of this system to the aromatic pyridine occurs readily 
and even contact with atmospheric oxygen will cause this conversion, making the study 
of the properties and characterization of dihydropyridines a difficult maneuver.
81a
 
Nevertheless, 1,4-dihydropyridines with biological activity have been identified and 
developed into FDA approved drugs.  
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2.1.1 Enantioselective Syntheses of 1,4-Dihydropyridines 
Recent developments in this reaction involved the formation of chiral 1,4-
dihydropyridines. In the early 1980’s the development of these compounds occurred with 
their introduction as calcium channel blockers for the treatment of hypertension. In 1980 
Shibanuma et al. reported the synthesis of (+) and (–)-nicardipine via the resolution of an 
intermediate carboxylic acid (Figure 2.2).
82
 Aminal formation allowed for the 
demethylation of one ester using sodium and 1-dimethylamino-2-propanol. Chiral 
resolution occurred by recrystallization using the chiral alkaloids cinchonine or 
cinchonidine to form diastereomeric salts and repeated until constant optical rotation was 
achieved. Washing with 1 M HCl removed the alkaloid and left the free acid, which 
could be esterified to nicardipine following the formation of the acid chloride using 
phosphorous pentachloride.
82
 This method has also been used in the synthesis of 
barnidipine.
83
 
 
Figure 2.2: Synthesis of (+) and (–)-nicardipine via alkaloid resolution 
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In 1981 a group at Bayer reported the enantioselective synthesis of nimodipine using a 
chiral auxiliary (Figure 2.3).
84
 The synthesis involved the Michael addition of (S)-2-
methoxy-2-phenylethyl 3-aminocrotonate 2.A with the condensation product of isopropyl 
acetoacetate and 3-nitrobenzaldehyde 2.B. With this chiral auxiliary, the product formed 
2.C was enantiomerically pure as the 4S isomer. Selective transesterification gave the 
pure (S)-nimodipine.
84
 
 
Figure 2.3: Stereoselective synthesis of nimodipine 
Meyers and Oppenlaender reported in 1986 the use of a chiral oxazoline 2.D to induce 
the diastereoselective addition of aryl lithium to a pyridine system, yielding a 
diastereomeric excess (de) of 78-90% (Figure 2.4).
85
 The same system was used again in 
1996, with Cheng et al. reporting that the aryl lithium preferentially added to the methyl 
ester, which could be circumvented by using a tert-butyl ester 2.E.
86
 This addition 
proceeded with a de of 67%. 
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Figure 2.4: Diastereoselective formation of 4-aryl-1,4-dihydropyridines using a chiral 
oxazoline 
In 1988, D. Enders et al. reported an enantioselective synthesis of 4-aryl-1,4-
dihydropyridines using chiral hydrazines (Figure 2.5).
87
 An asymmetric Michael addition 
of metalated chiral alkyl acetoacetate hydrazones 2.F to Knoevenagel acceptors 2.G and 
subsequent cleavage of the nitrogen-nitrogen bond resulted in products with enantiomeric 
excess (ee) between 84% and 98%.  
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Figure 2.5: Stereoselective synthesis of 4-aryl-1,4-dihydropyridines using chiral 
hydrazines 
Lipases from Pseudomonas were shown in 1991 to selectively cleave one of two ester 
groups of a symmetrical 1,4-dihydropyridine, providing an enantiomerically pure product 
(2.H, Figure 2.6).
88
  
 
Figure 2.6: Selective ester cleavage of symmetrical 1,4-dihydropyridine using 
Pseudomonas lipase 
Initial reactions were carried out in buffer at a pH of 5 giving the best ee of 15%. 
Utilizing an n-butanol and water mixture in a ten to one ratio without buffer resulted in an 
optimal ee of 97% in 31% yield. A higher yield was obtained by a shorter reaction time 
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with a loss of enantiomeric excess. The side product of this reaction is the di-acid and the 
yield for this compound increased over time.  
In 1994 Kosugi et al. reported the synthesis of optically pure 1,4-dihydropyridine 
derivatives via the diastereomeric separation of Hantzsch intermediates containing an 
(R)-1-phenylethylamino group (Figure 2.7).
89
 Similar to what Enders reported in 1988, 
Michael addition followed by the removal of the chiral auxiliary and cyclization gave the 
desired 4-aryl-1,4-dihydropyridine (2.I). 
 
Figure 2.7: Synthesis of chiral 4-aryl-1,4-dihydropyridines via diastereomeric 
intermediates 
The resolution of 4-aryl-1,4-dihydropyridine derivatives bearing isothioureido groups off 
the 2-methyl was described in 2006 by Moshtaghi et al. (Figure 2.8).
90
 Bromination of 
the methyl group followed by substitution with the thiourea resulted in the racemic 
product that was resolved using dibenzoyl-tartaric acid. 
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Figure 2.8: Synthesis of a chiral 4-aryl-1,4-dihydropyridine using tartaric acid resolution 
The use of chiral BINOL-phosphoric acid catalysts was reported by Evans and Gestwicki 
in 2009 resulting in up to >99% ee in 4-phenyl polyhydroquinoline derivatives (2.J, 
Figure 2.9).
91
 The cyclohexa-1,3-dione dimedone (2.K) was used with ethyl acetoacetate, 
ammonium acetate and various benzaldehydes in the presence of 10 mol% of catalyst in 
acetonitrile at room temperature to give a selection of substituted 4-aryl-1,4-
dihydropyridine derivatives in at least 87% ee.  
 
Figure 2.9: Use of chiral BINOL-phosphoric acid in the enantioselective synthesis of 4-
phenyl polyhydroquinolines 
Although a few methods exist for enantioselective synthesis of a 1,4-dihydropyridine 
system, chiral auxiliaries or chiral chromatography remain a mainstay in the syntheses of 
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these molecules.
85-89, 91-92
 Polyhydroquinolines that are formed via the Hantzsch 
dihyropyridine synthesis generally have only one stereocenter. Thus, a technique 
allowing for the stereoselective synthesis of 1,4-dihydropyridine derivatives with a 
second stereocenter would be a novel endeavor. 
2.1.2 Biological Activity of 1,4-Dihydropyridine Derivatives 
1,4-Dihydropyridines have long been known to have biological activity with the first 
observed activities being analgesic and muscle-relaxing properties.
93
 In the early 1970’s 
1,4-dihydropyridines were found to be calcium channel blockers (Figure 2.10).  
 
Figure 2.10: Calcium channel blockers on the market 
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These calcium antagonists reduce the influx of Ca
2+
 in the cells of the contractile system 
resulting in the direct damping of myocardial work-load metabolism, an increase in blood 
supply to the coronary vessels and a reduction in arterial flow resistance.
84
 The reduction 
of arterial flow resistance has made these compounds effective drugs in the treatment of 
hypertension and angina pectoris. The enantiomers of these compounds have been found 
to have opposite effects, with one being an agonist and one being an antagonist.
85, 92a, 94
 If 
racemic mixtures are used, one enantiomer should be more active than the other. 
Sirisha et al. have shown 1,4-dihydropyridine derivatives that display in vitro anti-cancer, 
anti-bacterial and anti-tubercular activities (Figure 2.11, 2.L, 2.M and 2.N).
95
 Anti-cancer 
activities for the most active compounds (2.L and 2.M) were on par with methotrexate in 
the single digit g/mL range against cancer cells from breast (MCF-7), colorectal (HT-
29) and skin (A431) cell lines. For compound (2.N), anti-tubercular activity was reported 
at 12.5 g/mL. Zones of inhibition against both gram positive and negative bacteria were 
also reported for this compound. Mehta and Verma have also shown 1,4-
dihydropyridines with zones of inhibition against both gram positive and negative 
bacteria.
96
  
1,4-Dihydropyridines have also been found to have anti-inflammatory properties via the 
inhibition of PDE4 enzymes,
97
 multidrug resistance reversal properties in anti-cancer 
drugs via the inhibition of P-glycoprotein
98
 and have even shown single digit micromolar 
activity in in vitro anti-leishmanial and anti-trypanosomal assays.
99
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Figure 2.11: 1,4-Dihydropyridines recently reported with anti-cancer, anti-tubercular and 
anti-bacterial properties 
2.2 1,4-Dihydropyridine Syntheses 
In 2010 a major high-throughput screening (HTS) was undertaken at St. Jude Children’s 
Research Hospital.
100
 This screen started with 309,474 unique compounds tested at 7 M 
against the 3D7 strain of Plasmodium falciparum. Approximately 1300 compounds 
displayed >80% activity with 561 having EC50s less than 2 M and a selectivity index of 
greater than ten when compared against two mammalian cell lines. Forty percent of these 
compounds were re-purchased and tested and 172 were re-confirmed by three separate 
laboratories to have anti-malarial activity. 
In early 2012, the groups from St. Jude Children’s Research Hospital, Novartis and 
GlaxoSmithKline published a review with results from independent anti-malarial HTS 
screenings.
101
 In an attempt to involve more research groups in the search for novel anti-
malarials, these results were published with the hope that drugs would become available 
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to further progress the elimination of malaria. As part of this testing, 4-
arylpolyhydroquinoline derivatives of asymmetric 1,4-dihydropyridines were identified 
as hits and it was decided that we would begin work on this chemotype. 
The synthesis of the 1,4-dihydropyridine derivatives began with 1,4,5,6,7,8-
hexahydroquinolines 2.O that were monosubstituted with phenyl derivatives at carbons 4 
and 7 (Figure 2.12). This substitution pattern leads to compounds with two stereocenters, 
with the formation of four stereoisomers. The presence of four stereoisomers required the 
identification of which stereoisomer is biologically active. The stereoselective synthesis 
of each stereoisomer was also investigated. Finally, a detailed structure-activity 
relationship (SAR) was envisioned to identify the most potent derivatives in combination 
with the most active stereoisomers. 
2.2.1 Synthetic Plan 
Chiral auxiliaries were used in order to add a preset chirality center to the molecules. It 
was believed that the formation of four diastereomers would facilitate a straightforward 
separation, allowing for the testing and crystallization of pure stereoisomers. Alongside 
this, it was thought that the six position methylene could be replaced with an oxygen, 
allowing for the formation of 1,4-dihydropyridine derivatives with structures of 4,5,7,8-
tetrahydro-1H-pyrano[4,3-b]pyridines 2.P (Figure 2.12). These derivatives could be 
formed from 6-phenyldihydro-2H-pyran-2,4(3H)-diones 2.Q, lactones that could 
potentially have chirality built in. The designed usage of the lactone for chiral synthesis 
led to the idea of utilizing a lactone library for the SAR. While the chiral syntheses were 
taking place, a racemic library would also be synthesized to determine the most active 
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compounds. The methylene and oxygen derivatives would have to be compared to 
determine if there was a loss or gain of activity between the two. 
 
Figure 2.12: Retroysynthesis of 1,4-dihydropyridine derivatives 
2.2.1.1 Comparison of Methylene and Oxygen Derivatives 
The replacement of a methylene with an oxygen could potentially create drastic changes 
between molecules. These isosteres have electronic differences that can play a significant 
role in solubility, molecular interactions and lipophilicity, among other properties. In the 
case of the 1,4-dihydropyridines, the syntheses of the two 6-position derivatives occurs 
via the same route. Ethyl acetoacetate, benzaldehyde, ammonium acetate and either 5-
phenylcyclohexan-1,3-dione 2.R or 6-phenyldihydro-2H-pyran-2,4(3H)-dione 2.Q can be 
heated at 120
º
C in acetonitrile within a sealed tube. Cyclization gives the asymmetric 1,4-
dihydropyridine as the major product (Figure 2.13). The diastereomers of 1,4,5,6,7,8-
hexahydroquinolines 2.O and 4,5,7,8-tetrahydro-1H-pyrano[4,3-b]pyridines 2.P can be 
separated via chromatography, with the derivatives of 2.P being more polar and more 
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easily separated via traditional flash chromatography. The 2.O derivatives were not 
readily separable by flash chromatography, but can be separated using preparative high-
pressure liquid chromatography (prep-HPLC). This ease of separability in the oxygen 
derivatives was a bonus for the use of these derivatives in the SAR. The diastereomeric 
pairs are labeled A and B, with A being the pair that moves more slowly on normal-phase 
silica and more quickly on reverse-phase silica. Crystal structure of 2.1 revealed that 2.1-
A is the 4,7-cis isomer and that 2.1-B is the 4,7-trans isomer (Figure 2.27). The crystal 
structure can also be used to explain why the trans isomer is formed in a slightly larger 
amount, as an edge-face interaction can be seen between the 4- and 7- aryl substituents. 
This interaction would lead to steric hindrance that results in the higher production of the 
trans stereoisomers. 
 
Figure 2.13: Synthesis of 1,4-dihydropyridine derivatives 
Initial 1,4-dihydropyridines utilized a 4-(2-chlorophenyl) and 7-(3,4-dimethoxyphenyl) 
substituent pattern. Comparison of the anti-malarial properties reveals that the activities 
are generally diminished when an oxygen replaces the methylene at the 6-position (Table 
2.1). Comparison of the A diastereomeric pairs cis-2.1 and 2.2-A show that the 
methylene version is between 7.9 and 14 times more active than the oxygen version 
across the four tested strains. The B diastereomers trans-2.1 and 2.2-B are significantly 
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more active than the A diastereomers cis-2.1 and 2.2-A with the methylene derivative 
again more active, although the W2 parasite was affected similarly by the two 
derivatives. The methylene version is between 1.2 and 19 times more active than the 
oxygen version across the four tested strains. 
Table 2.1: Comparison of the replacement of -CH2- with -O- at the 6-position 
 
Compound X A/B 
3D7 
EC50  n 
K1 
EC50  n 
W2 
EC50  n 
TM90-C2B 
EC50  n 
J774A.1 
EC50   
2.1 CH2 
cis 165 141 53.2 128 >20 
trans 13.5 15.7 40 4.9 >20 
mix 17.1 28 99 24.3 >20 
2.2 O 
A 2330 1390 418 1190 >20 
B 260 244 48.8 91.2 >20 
mix 372 323 66 180 >20 
 
The P. falciparum strains 3D7 and K1were provided by the MR4 Unit of the American 
Type Culture Collection (ATCC, Manassas, VA). Those two strains were the chloroquine 
sensitive strain 3D7 and the chloroquine resistant strain K1. Asynchronous parasites were 
maintained in culture based on the method of Trager.
102
  Parasites were grown in 
presence of fresh group O-positive erythrocytes (Key Biologics, LLC, Memphis, TN) in 
Petri dishes at a hematocrite of 4-6% in RPMI based media (RPMI 1640 supplemented 
with 0.5% AlbuMAX II, 25 mM HEPES, 25 mM NaHCO3 (pH 7.3), 100 µg/mL 
hypoxanthine, and 5 µg/mL gentamycin).  Cultures were incubated at 37°C in a gas 
mixture of 90% N2, 5% O2, 5% CO2. For EC50 determinations, 20 µL of RPMI 1640 with 
5 µg/mL gentamycin were dispensed per well in an assay plate (Corning 384-well 
mircotiter plate, clear bottom, tissue culture treated, catalog no. 8807BC). An amount of 
40 nL of compound, previously serial diluted in a separate 384-well white polypropylene 
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plate (Corning, catalog no. 8748BC), was dispensed to the assay plate by hydrodynamic 
pin transfer (FP1S50H, V&P Scientific Pin Head) and then an amount of 20 µL of a 
synchronized culture suspension (1% rings, 4% hematocrite) was added per well, thus 
making a final hematocrite and parasitemia of 2% and 1%, respectively. Assay plates 
were incubated for 72 h, and the parasitemia was determined by a method previously 
described:
103
 Briefly, an amount of 10 µL of the following solution in PBS (10X Sybr 
Green I, 0.5% v/v triton, 0.5 mg/ml saponin) was added per well.  Assay plates were 
shaken for 1 minute, incubated in the dark for 90 minutes, then read with the Envision 
spectrophotomer at Ex/Em of 485/535 nm. IC50s were calculated with the robust 
investigation of screening experiments (RISE) with four-parameter logistic equation. 
All synthesized 1,4-dihydropyridines were routinely tested against the clinically relevant 
multidrug resistant malarial strains W2 (chloroquine and pyrimethamine resistant) and 
TM90-C2B (chloroquine, mefloquine, pyrimethamine, and atovaquone resistant). The 
human malaria parasite P. falciparum has been grown in vitro in dilute human 
erythrocytes in RPMI 1640 media containing 10% heat inactivated plasma.
104
 
Concentration response data have been analyzed by a nonlinear regression logistic dose 
response model, and the 50% inhibition for each compound against the individual strains 
has been calculated as the effective concentrations (EC50). Generally, the 1,4-
dihydropyridines do not display signs of cytotoxicity at less than 20 μM, rendering 
cytotoxicity indices (CI = EC50(J774)/EC50(TM90-C2B)) of 1000 or more for the most 
active compounds. These results indicate that the 1,4-dihydropyridines are selective and 
nontoxic agents.  
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2.2.1.2 Synthetic Scheme with Chiral Auxiliaries 
Initial synthetic strategy for isolation of pure stereoisomers occurred with compound 2.1 
(SJ000025107, initial compound number from St. Jude Children’s Reseach Hospital100) 
after the separation of the diastereomeric pairs, cis-2.1 and trans-2.1. The enantiomers 
were thought to be separated by the transesterification of the ethyl ester with a chiral 
auxiliary, allowing for the separation of the newly formed diastereomers. 
Transesterification back to the ethyl ester would allow for the isolation of all four pure 
stereoisomers of 2.1.  
Transesterification was first attempted using (S)-1,2-isopropylideneglycerol in 
tetrahydrofuran (THF) at high temperature within a sealed tube (Figure 2.14). No reaction 
occurred over five hours, so 16 equivalents of acetic acid were added in the hopes of 
having an acid catalyzed reaction occur. Heating for an additional 15 hours resulted in no 
reaction, with compound 2.1 remaining intact.  
 
Figure 2.14: Transesterification attempt with (S)-1,2-isopropylideneglycerol 
Next, hydrolysis to the acid was attempted using 2 equivalents of lithium hydroxide in 
THF and water at 65
º
C for 24 hours and separately with 10 equivalents of aqueous 
hydrochloric acid in THF and water at 65
º
C for 36 hours (Figure 2.15).
105
 Both hydrolysis 
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attempts resulted in no reaction occurring, showing that the reactivity of the 3-
carboxylate carbon is reduced in this system. 
 
Figure 2.15: Hydrolysis with acid or base 
Hydrolysis of the ester was thought to occur more readily by the use of an ester group 
that was more easily removed. tert-Butyl acetoacetate was used in place of ethyl 
acetoacetate in a trial run to form the tert-butyl ester 2.3 (Figure 2.16). The stable tert-
butyl carbocation was believed to be formed via the reaction with acid, leaving the free 
carboxylic acid. Reaction with 15 equivalents of hydrochloric acid in water at 100
º
C for 3 
hours resulted in no reaction. 
 
Figure 2.16: Hydrolysis of the tert-butyl ester 2.3 
As formation of the carboxylic acid did not readily occur, treating the carboxylate as a 
leaving group was the next option. (9H-fluoren-9-yl)methyl acetoacetate 2.4 was 
synthesized and used in the formation of the fluorenylmethyl ester 2.5. Treatment of this 
compound with 1.5 equivalents of 1,8-diazabicyclo[5.4.0]-undec-7-ene (DBU) at room 
temperature resulted in the β-elimination of 9-methylene-9H-fluorene and the release of 
the acid 2.6. At long last the free carboxylic acid was formed. 
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Figure 2.17: Synthesis of the 3-carboxylic acid via β-elimination 
In order to derivatize the acid to form the chiral esters and amides, a carbodiimide 
coupling was attempted using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) 
and 4-dimethylaminopyridine (DMAP) in dichloromethane (DCM) or 
dimethylformamide (DMF) to couple the acid with the primary alcohol (S)-1,2-
isopropylideneglycerol, the secondary amide (S)-4-benzyl-2-oxazolidinone or the 
secondary alcohol (S)-mandelic acid (Figure 2.18).  
 
Figure 2.18: Acid derivatization attempts 
No reactions were observed so a Mitsunobu reaction was attempted with the same acid 
2.6 and primary alcohol with diisopropyl azodicarboxylate (DIAD) and 
triphenylphosphine in THF, again with no reaction. Chlorination of the acid to the acyl 
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chloride with thionyl chloride was ineffective, as reactions in DCM or DMF followed by 
quenching with even the small primary alcohol methanol resulted in no formation of the 
ester.
82-83, 89, 106
 As a final derivatization effort, we attempted to synthesize the anhydride 
using an acid chloride. (S)-Mosher’s acid chloride was added to the acid in THF 
following the addition of 1.2 equivalents of sodium hydride. A reaction did occur with 
these conditions, although oxidation of the 1,4-dihydropyridine was believed to occur 
with decomposition of the side chain carboxylate. 
Synthesis then proceeded with the formation of chiral acetoacetate derivatives with the 
idea that if a chiral auxiliary could not be added to the 1,4-dihydropyridine acid 2.6, it 
may be possible to add it prior to the cyclization. Two chiral auxiliaries were employed: a 
threonine derivative 2.7 and an oxazolidinone derivative 2.8 (Figure 2.19). 
 
Figure 2.19: Synthesis of chiral auxiliary acetoacetates 
 These chiral auxiliary containing acetoactetates and their enantiomers were employed in 
the cyclization to form diastereomeric sets of polyhydroquinolines and were utilized due 
to literature reports describing transesterification possibilities and were incorporated into 
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the acetoacetate portion of the molecule.
107
 The L-threonine derivative (2S,3R)-2.7 was 
cyclized via the Hantszch reaction and formed three peaks (2R,3S)-2.9 by HPLC (Figure 
2.20).
107c
 These three peaks, 2.9-P1, 2.9-P2 and 2.9-P3, were separated using prep-HPLC 
(RP18) with an isocratic system utilizing 55:45 acetonitrile to water and 0.05% 
trifluoroacetic acid (TFA). A note to the reader, the stereochemistry changes between 2.7 
and 2.9 due to a change in IUPAC numbering system of the threonine side chain.  
 
Figure 2.20: Analytical RP18 HPLC trace of threonine diastereomers 
After separation of the three peaks using preparative HPLC, analytical chiral HPLC using 
a Lux column confirmed that each peak was a single isomer. NMR of each threonine 
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derivative, however, gave a surprising twist to what was believed to be three different 
compounds (Figure 2.21).  
 
Figure 2.21: Carbon NMR of threonine derivative 2.9-P1 (top) and 2.9-P2 (bottom) 
between 103 and 171 ppm 
The NMR of 2.9-P1 and 2.9-P3 were similar to each other, but comparison with 2.9-P2 
revealed that there were an abnormally large number of peaks present. This led to the 
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conclusion that 2.9-P2 was a mixture of two diastereomers that could not be separated by 
RP18 prep-HPLC. 2.9 was synthesized from both D- and L- threonine, resulting in either 
(2S,3R)-2.9 or (2R,3S)-2.9. 
An immediate concern was that upon transesterification the ethyl ester versions of 2.9-P1 
and 2.9-P3 would reveal that they were enantiomers and that this method would not 
allow for the separation of all four stereoisomers. Luckily, transformation of 2.9-P2 to the 
ethyl ester 2.1 resulted in the formation of a pair of diastereomers that could be separated 
by RP18 HPLC, showing that all four stereoisomers were indeed formed and could be 
separated (Figure 2.22). 
 
Figure 2.22: Synthesis of pure 1,4-dihydropyridine stereoisomers via (2S,3R)-2.9-P2 
Formation of the ethyl ester 2.1 from the threonine ester 2.9 occurred via two steps. First, 
a β-elimination with DBU removed the threonine portion, leaving the free carboxylic acid 
2.6. Next, the acid was reacted with ethyl iodide and potassium carbonate to give the 
ethyl ester 2.1.  
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X-ray crystallography is an excellent technique for determination of crystal packing 
structure of molecules and also for the identification of stereochemistry of unknown 
stereocenters. In order for this technique to be used, crystals of an adequate size and 
quality need to be grown. As identification of the unknown stereochemistry of the 2.1 
derivatives was a high priority, crystallization with ethanol, methanol, isopropanol, 
DCM, DMF, acetonitrile, toluene and acetone was attempted via evaporation of solvent. 
Unfortunately, using these conditions no crystals of 2.1, 2.9-P1 or 2.9-P3 could be 
formed. 
A second chiral acetoacetate was used for the preparation of diastereomeric 1,4-
dihydropyridines. The oxazolidinone 2.8 also cyclized via the Hantszch reaction and 
formed three peaks by HPLC (Figure 2.23).  
 
Figure 2.23: Synthesis of pure 2.1 stereoisomers via the chiral oxazolidinone side chain 
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These three 2.10 peaks were separated using RP18 prep-HPLC under isocratic conditions 
with 1:1 acetonitrile to water and 0.05% trifluoroacetic acid (TFA) (Figure 2.24). These 
three 2.10 peaks correlated to three of the possible stereoisomers, unlike 2.9 where one of 
the peaks consisted of two diastereomers. NMR of each 2.10 peak revealed each peak as 
one isomer. 
 
Figure 2.24: Analytical RP18 HPLC trace of oxazolidinone diastereomers 
Formation of the ethyl ester 2.1 occurred at 150
º
C in a sealed tube with ethanol and 
titanium (IV) ethoxide with a poor yield of 28% (Figure 2.20).
107a, b
 This esterification 
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was attempted without the addition of the lewis acid with no reaction occurring, 
indicating that the strongly acidic nature of the titanium (IV) is necessary for any reaction 
to proceed. The poor reaction with the strong lewis acid again underlines the poor 
reactivity of the 3-carboxylate of this 1,4-dihydropyridine system. 
The use of both oxazolidinone enantiomers, (R)-2.8 and (S)-2.8, ensured the formation of 
all four 2.1 stereoisomers. Each 2.8 enantiomer results in the cis compounds (4S,7S)-2.1 
and (4R,7R)-2.1 and one trans-2.1. The oxazolidinone enantiomers (R)-2.8 and (S)-2.8 
each react to form three respective diastereomers, (R)-2.10 and (S)-2.10 (Figure 2.25).  
 
Figure 2.25: Formation of six 2.10 stereoisomers as three enantiomeric pairs 
Analytical RP18 HPLC analysis of the ethyl esters 2.1 proved that 2.10-P1 and 2.10-P2 
are 2.1-A enantiomers (Figure 2.26). 2.10-P3 corresponds to one 2.1-B enantiomer and is 
formed in the lowest amount from 2.8, as seen by HPLC (Figure 2.24). Crystallization 
with ethanol, methanol, isopropanol, DMF, acetonitrile, toluene and acetone was 
attempted with 2.10 via evaporation of solvent. Although the alcohols, acetonitrile and 
DMF all gave crystals, none were of a high enough quality for X-ray identification, thus 
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vapor diffusion technique was implemented using dimethyl sulfoxide (DMSO) as the 
solution solvent and an ethanol/water mix as the diffusion solvents.  
 
Figure 2.26: Identification of 2.1 ethyl esters of 2.10-P1 and 2.10-P2 as enantiomers 
Using this technique a crystal of both (R)-2.10-P1 and (S)-2.10-P1 were formed and X-
ray crystallography allowed the assignation of absolute stereochemistry for the 2.1-A 
enantiomers. The 2.1-A 1,4-dihydropyridines are cis dihydropyridines and (R)-2.10-P1 
had (4S,7S) stereochemistry while (S)-2.10-P1 had (4R,7R) stereochemistry. The crystal 
structure of 2.10-P1 had two independent conformations in the crystal lattice (Figure 
2.27). The 4-aryl substituent resides in a pseudoaxial conformation with the 7-aryl being 
either axial or equatorial. 
Analytical RP18 HPLC using a chiral Lux column allowed for the comparison of 2.1-A 
enantiomers formed from 2.10 with the 2.1-A enantiomers from 2.9. This method proved 
that 2.1-A from (2S,3R)-2.9-P2 has (4S,7S) stereochemistry and 2.1-A from (2R,3S)-2.9-
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P2 has (4R,7R) stereochemistry, the same as (R)-2.10-P1 and (S)-2.10-P1, respectively 
(Figure 2.28). 
 
Figure 2.27: Crystal structure of (R)-2.10-P1 with equatorial 7-substituent (top) and axial 
7-substituent (bottom) 
Utilizing these two chiral auxiliaries, we were able to determine the absolute 
configuration of the 2.1-A enantiomers, determine the relative stereochemistry of the 2.1-
B enantiomers as trans conformers and isolate all four stereoisomers of 2.1 in pure form. 
The use of the 2.7 threonine derivative provided a higher yielding method than the use of 
the 2.8 oxazolidinone derivative (Table 2.2).  
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Figure 2.28: Synthesis of (4S,7S)-2.1-A from (2S,3R)-2.9-P2 and (R)-2.10-P1 
While the synthesis requires three more steps, a 27.4% overall yield was obtained 
compared to a 10.5% yield with the oxazolidinone. Separation using the preparative 
HPLC also occurred more easily with the threonine derivative, all four stereoisomers are 
formed with the use of one auxiliary enantiomer and more than 50% of the product 
formed is the more active 4,7-trans conformer. Crystal structures were found using 2.8, 
but in all other ways 2.7 was the better auxiliary.  
Table 2.2: Comparison of oxazolidinone and threonine auxiliaries 
 Oxazolidinone Threonine 
Cost of auxiliary (Sigma) (R) - $117/5 g – (S) - $95/5 g L - $22/10 g – D - $33/5 g 
Number of Steps 3 6 
Total Yield 10.5% 27.4% 
Stereoisomers formed 3 4 
Prep-HPLC Separation Peak overlap No overlap 
Amount of B <25% of total >50% of total 
 
2.2.1.3 Synthetic Schemes for Chiral β-Ketolactones 
The reasoning behind the use of the lactone was the setting of one stereocenter prior to 
formation of the 1,4-dihydropyridine core. If the stereochemistry of the 7-position could 
be set, isolation of pure stereoisomers would depend solely on separation of two 
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diastereomers. As shown in Table 2.1, the replacement of a methylene with an oxygen at 
the 6-position reduced the activity significantly. It was believed that the easier formation 
of pure stereoisomers would make up for the reduced activity and the performed SAR 
would at the least lead to more active compounds that could be reevaluated with the 
methylene unit.  
Synthesis of the racemic lactone 2.11 began with the formation of the dianion of ethyl 
acetoacetate prepared from the consecutive additions of sodium hydride and n-butyl 
lithium to the acetoacetate in THF between -20 and 0
º
C (Figure 2.27). This was followed 
by the addition of a benzaldehyde derivative, yielding the secondary benzyl alcohol 2.12. 
This alcohol was cyclized with KOH or p-toluenesulfonic acid (pTSA) to yield the β-
ketolactone 2.11.
108
 
 
Figure 2.29: Example of the formation of a β-ketolactone from a benzaldehyde 
With a usable synthesis for the racemic lactone 2.11, our efforts turned toward finding a 
highly stereoselective synthesis of a chiral lactone. The idea was that if the benzyl 
alcohol 2.12 could be formed with high enantioselectivity then the cyclization would 
yield the chiral lactone. 
Initial efforts began using the Mukaiyama aldol route using Chan’s diene 2.13, the di-
trimethylsilyl (TMS) protected methyl acetoacetate. Addition of Chan’s diene to the 
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aldehyde in the presence of (R)-BINOL with lithium chloride and titanium (IV) 
isopropoxide yielded the TMS protected benzyl alcohol (Figure 2.28).
109
 Deprotection of 
the TMS group with pyridinium para-toluenesulfonate (PPTS) resulted in a low 
conversion. Optical rotation of the isolated alcohol 2.14 showed a low enantiomeric 
excess (ee) when compared with the reported literature value.  
 
Figure 2.30: Mukaiyama aldol route using Chan’s diene 
 
Keck allylation was attempted using allyltributylstannane, (R)-BINOL and titanium (IV) 
isopropoxide with 3,4-dimethoxybenzaldehyde in dichloromethane (DCM) with 
molecular sieves at -20
º
C (Figure 2.29).
110
 After 4 days, less than 20% yield was obtained 
with 98% ee. Mitsunobu reaction was attempted to determine if one Keck allylation could 
yield both enantiomers, but the reduction of ee to 20% rendered that idea obsolete. A 
more electron deficient benzaldehye was used with the hopes of enhancing the 
nucleophilic attack on the aldehyde. Keck allylation of 4-bromobenzaldehyde to form 
2.15 followed by oxidative cleavage to the β-hydroxyaldehyde 2.16, C-H insertion using 
ethyl diazoacetate and tin (II) chloride to form 2.17, cyclization to the β-ketolactone 2.18 
and asymmetric Hantzsch reaction resulted in a 40% ee of 2.19 that was unacceptable. At 
this point it was believed that the 2,6-lutidine was causing a drop in ee. 
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Figure 2.31: Hantzsch reaction using a chiral lactone derivative 2.16 
The next route began with an allylation using Brown’s reagent.111 This reaction 
proceeded at -90
º
C in diethyl ether with the addition of (+)-B-
allyldiisopinocampheylborane to the 3,4-dimethoxybenzaldehyde (Figure 2.30). After 
thirty minutes a 75% yield and 99% ee was obtained and the compound proceeded 
through the same steps as the Keck allyation product, minus the addition of lutidine. With 
this reaction sequence, and especially in the oxidative cleavage step, many inseparable 
impurities were formed. This led to cyclization with pTSA giving the styrene elimination 
product 2.20 as the major product. When less pTSA was used the reaction was stagnant 
and low yielding. At this point it was believed that protecting the benzyl alcohol 2.21 
would help to increase the yield and allow for easier purification. With a tributylsilyl 
(TBS) protecting group, the yield from the benzyl alcohol 2.21 to the β-ketoester 2.22 
dramatically increased from 20% to 52%, even with the extra protection step involved. 
The deprotection step was troublesome where the use of HCl, PPTS, HF or 
tetrabutylammonium fluoride (TBAF) resulted in an unclean reaction, again yielding a 
large amount of the elimination product 2.20 (Figure 2.30). 
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Figure 2.32: Brown’s allylation steps using a TBS protected benzyl alcohol 
Due to the large amounts of styrene elimination product 2.20 being formed, we decided 
to add the β-ketone last in order to eliminate a source of conjugation with the alkene. 
Cross metathesis using Grubb’s second generation catalyst of the benzyl alcohol 2.21 
obtained from Brown’s allylation with ethyl acrylate provided a Michael acceptor 2.25 
that could have an oxygen placed in the correct location for oxidation to the ketone 
(Figure 2.31).
112
 Reaction with potassium tert-butoxide and benzaldehyde gave a six-
membered acetal 2.26 that was added to the Michael acceptor in the fashion hoped for.
112
 
Using pTSA monohydrate in methanol, it was expected that the acetal would be 
hydrolyzed to the diol and that the benzyl alcohol would lactonize to give the desired 
lactone that could be oxidized to the β-ketolactone 2.11. In reality, the conditions gave a 
methanol addition product 2.27 that eliminated the compound for further use. 
Dichloromethane in the place of methanol resulted in a low conversion rate with the diol 
as a minor product and no cyclization. The use of acetic acid and water in a four to one 
ratio resulted in no reaction.  
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Figure 2.33: Cross metathesis and Michael addition of the Brown allylation product 
One more attempt using Brown’s allylation product involved a ring closing metathesis 
(RCM). The benzyl alcohol product 2.21 was reacted with acryloyl chloride in DCM with 
either triethylamine (TEA) or pyridine, giving a compound 2.28 that was primed for the 
RCM (Figure 2.32). Using Grubb’s first generation catalyst, the six membered alkene 
2.29 was formed, albeit in 82% ee when TEA was used in the previous step and 88% ee 
when pyridine was used.
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Figure 2.34: Ring-closing metathesis route 
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After multiple attempts to form the chiral lactone derivative, it was decided that the 
benzyl position was not stable enough to maintain a stereocenter with high ee. As the 
SAR was already well underway at this point, the racemic lactone syntheses would 
continue in the attempts to find more active substituents for the 1,4-dihydropyridine. 
Isolation of a pure stereoisomer could then proceed via a chiral auxiliary route. 
2.2.2 Structure-Activity Relationship of 1,4-Dihydropyridines 
2.2.2.1 Structure-Activity Relationship at 4- and 7-Positions 
Synthetic manipulations of the 1,4-dihydropyridine began with ortho-, meta- and para- 
substitutions of the 4-phenyl ring with chloro-, methyl- or methoxy- substituents to 
determine the effect of electronics and sterics on activity. As can be seen by compounds 
2.2B and 2.32-B, chloro and methyl substitutions at the ortho position result in 
submicromolar activity, with the methyl derivative displaying better activity against the 
3D7 and K1 strains and the chloro derivative displaying better activity against the W2 
and TM90-C2B strains (Table 2.3).  Submicromolar activity was not seen with any meta 
substitutions. Substitution at the para position resulted in submicromolar activities with 
chloro and methyl substituted compounds 2.31 and 2.34-B, with the para chloro 
derivative having better activity across the board. 
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Table 2.3: 4-phenyl modifications
a 
 
Compound X R A/B 
3D7 
EC50  n 
K1 
EC50  n 
W2 
EC50  n 
TM90-C2B 
EC50  n 
J774A.1 
EC50   
2.1 CH2 2-Cl 
cis 165 141 53.2 128 >20 
trans 13.5 15.7 40 4.9 >20 
mix 17.1 28 99 24.3 >20 
2.2 O 2-Cl 
A 2330 1390 418 1190 >20 
B 260 244 48.8 91.2 >20 
mix 372 323 66 180 >20 
2.30 O 3-Cl 
A >10000 >10000 3930 >5000 >20 
B >10000 >10000 1640 >5000 >20 
mix >10000 >10000 2700 4330 >20 
2.31 O 4-Cl 
A 769  633  470  822  >20 
B 47.6  53.8  49.0  65.6  >20 
mix 91.8  160 87.0  102 >20 
2.32 O 2-CH3 
A 1270  2050  1720 4030 >20 
B 38.5  59.7  56.9 189  >20 
mix 72.7 123 144 300 >20 
2.33 O 3-CH3 
A >10000  >10000  3810 4070 >20 
B >10000  >10000 2640  >5000 >20 
mix >10000 >10000 4210 >5000 >20 
2.34 O 4-CH3 
A >10000  >10000 2500 4220 >20 
B 638  605  230  327  >20 
mix 1250  1610 534  995  >20 
2.35 O 2-OCH3 
A >5600 >5600 >5000 >5000 n/d 
B 2050 >5500 732 >5000 n/d 
mix >5500 >5500 1290 >5000 n/d 
2.36 O 3-OCH3 
A >10000  >10000  2980 2710 >20 
B >10000  >10000  2920  2930 >20 
mix >10000 >10000 >5000 >5000 >20 
2.37 O 4-OCH3 
A >10000 >10000 3150 >5000 >20 
B >10000 >10000 1780 2710 >20 
mix >10000 >10000 2400 3120 >20 
aChloroquine (EC50K1 = 1360 ± 960 nM, EC503D7 = 48 ± 25 nM, EC50W2 = 96.7 ± 56.3 ng/mL, EC50TM90-C2B = 
55.5 ± 27.8 ng/mL), mefloquine (EC50K1 = 31 ± 18 nM, EC503D7 = 62 ± 31), atovaquone (EC50W2 = 0.574 ± 0.306 
ng/mL, EC50TM90-C2B = 7.54 ± 4.65 µg/mL) and dihydroartemisin (EC50W2 = 1.41 ± 0.29 ng/mL, EC50TM90-C2B = 
1.76 ± 0.12 ng/mL) are the internal controls for the in vitro anti-malarial activity assays. Podophyllotoxin is the 
internal control for the in vitro cytotoxicity assay with EC50 = 250 ± 10 nM against J774A.1. 
 
Extended aromatic systems at the 4-position, including 2- and 3-naphthyl and 4-(4-
biphenyl) (Table 2.4, 2.40-2.42), decrease the activity of the 1,4-dihydropyridine system, 
with no submicromolar activities. The 4-bromophenyl 2.38 fared better but was less 
active than the 4-chlorophenyl 2.31. The 4-nitrophenyl 2.39-B has submicromolar 
activity against W2 and TM90-C2B only.  
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Table 2.4: Aromatic changes at 4-position
a
 
 
Compound R A/B 
3D7 
EC50  n 
K1 
EC50  n 
W2 
EC50  n 
TM90-C2B 
EC50  n 
J774A.1 
EC50   
2.38 4-bromophenyl 
A 1450 3370 2350 >5000 >20 
B 59 341 170 285 >20 
mix 213 634 375 725 >20 
2.39 4-nitrophenyl 
A >10000 >10000 2610 3000 >20 
B 2710 2200 317 386 >20 
mix >10000 >10000 >5000 >5000 >20 
2.40 1-naphthyl 
A >10000 >10000 2850 2130 >20 
B >10000 >10000 3180 3270 >20 
mix >10000 >10000 >5000 >5000 >20 
2.41 2-naphthyl 
A >10000 >10000 4110 >5000 >20 
B >10000 >10000 3040 >5000 >20 
mix >10000 >10000 1620 >5000 >20 
2.42 4-(4-biphenyl) 
A >10000 >10000 >5000 >5000 >20 
B >10000 >10000 1640 1990 >20 
mix >10000 >10000 2220 >5000 >20 
aChloroquine (EC50K1 = 1360 ± 960 nM, EC503D7 = 48 ± 25 nM, EC50W2 = 96.7 ± 56.3 ng/mL, EC50TM90-C2B 
= 55.5 ± 27.8 ng/mL), mefloquine (EC50K1 = 31 ± 18 nM, EC503D7 = 62 ± 31), atovaquone (EC50W2 = 0.574 
± 0.306 ng/mL, EC50TM90-C2B = 7.54 ± 4.65 µg/mL) and dihydroartemisin (EC50W2 = 1.41 ± 0.29 ng/mL, 
EC50TM90-C2B = 1.76 ± 0.12 ng/mL) are the internal controls for the in vitro anti-malarial activity assays. 
Podophyllotoxin is the internal control for the in vitro cytotoxicity assay with EC50 = 250 ± 10 nM against 
J774A.1. 
 
Next, the 7-phenyl ring was looked at synthetically with the same ortho-, meta- and para- 
substitutions with chloro-, methyl- or methoxy- substituents. Substitution at the para 
position resulted in one compound with submicromolar activity in the 3D7 and K1 
assays, the chloro derivative 2.45-A (Table 2.5). The 2.45-B and 4-methoxy derivative 
2.51-B gave single digit micromolar activity in these assays, with the 4-methyl derivative 
2.48-B giving single digit micromolar activity against K1 only. Submicromolar activity 
was seen in the W2 assay with the 4-methyl 2.48-B and the 4-methoxy 2.51-B. Single 
digit micromolar activity in the TM90-C2B assay was found with these compounds. Meta 
substitution again gave one compound with submicromolar activity in the 3D7 and K1 
assays with single digit micromolar activity in the W2 and TM90-C2B assays, the 
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methoxy derivative 2.50-B. The 2.50-A derivative had single digit micromolar activity 
against the all strains besides K1. W2 was the only strain to show activity when ortho 
substitution was present, with the o-methyl 2.46-B having submicromolar activity. 
Table 2.5: 7-Phenyl mofications
a
 
 
Compound R A/B 
3D7 
EC50  n 
K1 
EC50  n 
W2 
EC50  n 
TM90-C2B 
EC50  n 
J774A.1 
EC50   
2.43 2-Cl 
A >5500 >5500 2250 >5000 n/d 
B >5500 >5500 >5000 >5000 n/d 
mix >6000 >6000 3070 >5000 n/d 
2.44 3-Cl 
A >6000 >6000 >5000 >5000 n/d 
B >6000 >6000 2050 4030 n/d 
mix >6000 >6000 3260 4130 n/d 
2.45 4-Cl 
A 510 560 2060 2030 n/d 
B 2860 2160 1150 4060 n/d 
mix >5500 >5500 1720 2260 n/d 
2.46 2-CH3 
A >5000 >5000 4610 4370 n/d 
B >5000 >5000 711 4080 n/d 
mix >5000 >5000 4430 4130 n/d 
2.47 3-CH3 
A >5000 >5000 >5000 >5000 n/d 
B >6000 >6000 2110 4350 n/d 
mix >5000 >5000 3250 >5000 n/d 
2.48 4-CH3 
A >5000 >5000 >5000 >5000 n/d 
B >6000 1583 923 3310 n/d 
mix >5000 >5000 1870 >5000 n/d 
2.49 2-OCH3 
A >6000 >6000 >5000 >5000 n/d 
B >5500 >5500 4050 3840 n/d 
mix >6000 >6000 4050 4240 n/d 
2.50 3-OCH3 
A 2133 >7000 2260 2280 n/d 
B 626 363 1490 2260 n/d 
mix 2417 >6000 2100 2650 n/d 
2.51 4-OCH3 
A >7000 >7000 4480 4240 n/d 
B 2155 1960 871 2730 n/d 
mix >7000 >7000 1670 3830 n/d 
aChloroquine (EC50K1 = 1360 ± 960 nM, EC503D7 = 48 ± 25 nM, EC50W2 = 96.7 ± 56.3 ng/mL, 
EC50TM90-C2B = 55.5 ± 27.8 ng/mL), mefloquine (EC50K1 = 31 ± 18 nM, EC503D7 = 62 ± 31), atovaquone 
(EC50W2 = 0.574 ± 0.306 ng/mL, EC50TM90-C2B = 7.54 ± 4.65 µg/mL) and dihydroartemisin (EC50W2 = 
1.41 ± 0.29 ng/mL, EC50TM90-C2B = 1.76 ± 0.12 ng/mL) are the internal controls for the in vitro anti-
malarial activity assays. Podophyllotoxin is the internal control for the in vitro cytotoxicity assay with 
EC50 = 250 ± 10 nM against J774A.1. 
 
As can be seen by Tables 2.3 and 2.4, changes to the 4-aryl position can increase the 
activity of the new compound or severely limit it. Phenyl substitution of 4-halo, 4-methyl, 
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2-chloro or 2-methyl results in compounds with submicromolar activities, with the best 
activities found with a 4-chloro or a 2-methyl, compounds 2.31-B and 2.32-B. Extended 
aromatic systems such as naphthyl or biphenyl completely remove the activity from 3D7 
or K1 and may display low micromolar activity in W2 and TM90-C2B. 
Substitution of the 7-phenyl system also plays a distinct role on activity (Table 2.5). Most 
of the mono-substituted compounds are inactive against 3D7 and K1, with the exceptions 
of the 4-chloro 2.45-A and the 3-methoxy 2.50-B having submicromolar activities. The 
same can be said for W2 and TM90-C2B, as no compounds displayed submicromolar 
activity against TM90-C2B while the 2-methyl 2.46-B, 4-methyl 2.48-B and the 4-
methoxy 2.51-B had submicromolar activity against W2. Comparision of Table 2.4 with 
compound 2.2 highlights the importance of a disubstituted phenyl substituent at the 7-
position.  
2.2.2.2 Structure-Activity Relationship of the 2- and 3-Positions 
To test the importance of the ester functional group, a number of derivatives were made 
by varying the ester substituent at the 3-position. The benzyl ester 2.57 did not have good 
activity (Table 2.6). A tert-butyl 2.56-B or n-propyl 2.55-B ester had similar activities 
against K1, W2 and TM90-C2B, while the tert-butyl had no activity against the 3D7 
strain. The ethyl ester (Table 2.2, 2.2-B) was more active than either ester. Changing the 
group at C2 revealed that extending the chain increases the activity, with n-propyl 2.52-B 
enhancing the activity against 3D7 and K1 while keeping in the range of the methyl 
against W2 and TM90-C2B. Also, a 2-ethoxy-2-oxoethyl 2.53-B increased activity 
against 3D7 and K1 with a mild decrease against W2 and TM90-C2B. The 2.53-A 
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diastereomers have a much better activity against all four strains when compared to the 
2.2-A diastereomers and has activity better than or the same as 2.53-B. A 2-methoxyethyl 
group with a methyl ester 2.54-B had better activity against 3D7 and K1 and lower 
activity against W2 and TM90-C2B compared to 2.2-B. Attempts to place a phenyl group 
at the 2-position resulted in no 1,4-dihydropyridine formation, thus the  activity for an 
aromatic group could not be seen. 
Table 2.6: 2- and 3-position modifications
a
 
 
Compound R1 R2 A/B 
3D7 
EC50  n 
K1 
EC50  n 
W2 
EC50  n 
TM90-C2B 
EC50  n 
J774A.1 
EC50   
2.52 Et nPr 
A 811 418 >5000 >5000 >20 
B 16.1 9.2 48.7 114 >20 
mix 29 15.5 261 718 >20 
2.53 Et 
2-ethoxy-2-
oxoethyl 
A 38.1 13.6 133 312 >20 
B 119 77.6 124 346 >20 
mix 58.7 22.2 346 671 >20 
2.54 Me 
2-methoxy 
ethyl 
A 2440 >10000 1690 4190 >20 
B 86.6 124 180 746 >20 
mix 237 315 432 962 >20 
2.55 nPr Me 
A 2360 >7000 2400 >5000 >20 
B 458 332 205 1370 >20 
mix 1670 1630 62.1 1210 >20 
2.56 tBu Me 
A >13000 >13000 1230 2810 >20 
B >13000 272 302 950 >20 
mix >13000 2650 510 2520 >20 
2.57 Bn Me 
A >11800 >11800 >5000 >5000 >20 
B >9100 >9100 3230 >5000 >20 
mix >7500 >7500 1070 >5000 >20 
aChloroquine (EC50K1 = 1360 ± 960 nM, EC503D7 = 48 ± 25 nM, EC50W2 = 96.7 ± 56.3 ng/mL, EC50TM90-C2B = 
55.5 ± 27.8 ng/mL), mefloquine (EC50K1 = 31 ± 18 nM, EC503D7 = 62 ± 31), atovaquone (EC50W2 = 0.574 ± 0.306 
ng/mL, EC50TM90-C2B = 7.54 ± 4.65 µg/mL) and dihydroartemisin (EC50W2 = 1.41 ± 0.29 ng/mL, EC50TM90-C2B = 
1.76 ± 0.12 ng/mL) are the internal controls for the in vitro anti-malarial activity assays. Podophyllotoxin is the 
internal control for the in vitro cytotoxicity assay with EC50 = 250 ± 10 nM against J774A.1. 
 
Changing of the alkyl substituent on the 3-position ester did not form a compound with 
better activity than the original ethyl ester, 2.2. The benzyl ester had no activity while a 
tert-butyl ester or n-propyl ester each showed submicromolar activities in three of the 
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four assays (compounds 2.55-2.57). The ethyl ester is clearly a better compound than 
these other three. 
Substitution at the 2-position did, however, create some interesting compounds. 
Elongation of the methyl 2.2 to a propyl 2.52 formed a compound with better activity in 
half of the assays. Replacement with some oxygenated ethyl derivatives resulted in some 
B compounds 2.53-B and 2.54-B with better activity in half of the assays and worse in 
the other half, while the 2.53-A oxygenated ethyl derivative fared much better than the 
methyl 2.2A.  
2.2.2.3 A Few Polyhydroquinoline Derivatives 
The synthesis of a 2-phenylpolyhydroquinoline derivative 2.58 allowed for biological 
screening with a 2-aryl substituent. The activity of this molecule was less than that for the 
methyl derivative, 2.1 (Table 2.7). The 4-(4-chlorophenyl) derivative 2.59-B was slightly 
more active than the 2-chloro version 2.1-B in all assays except for the TM90-C2B, 
where 2.1-B is 12 times more active. Replacing the 2-position methyl of 2.59-B with a 2-
ethoxyethyl 2.60-B creates a compound with better across the board activity. 
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Table 2.7: Polyhydroquinoline derivatives with C2 and C4 changes
a
 
 
Compound R1 R2 R3 A/B 
3D7 
EC50  n 
K1 
EC50  n 
W2 
EC50  n 
TM90-C2B 
EC50  n 
J774A.1 
EC50   
2.58 Et phenyl 2-Cl 
A 3720 >10900 2260 3990 >20 
B 40.5 46.7 119 256 >20 
mix 176 92.3 274 570 >20 
2.59 Et methyl 4-Cl 
A 264 221 284 511 >20 
B 10.3 9.3 27.3 60.8 >20 
mix 16.3 18.9 70.4 103 >20 
2.60 Me 
2-
ethoxy 
ethyl 
4-Cl 
A 145 130 191 434 >20 
B 2.5 15 3.9 7.1 >20 
mix 6.3 11 29.4 20 >20 
aChloroquine (EC50K1 = 1360 ± 960 nM, EC503D7 = 48 ± 25 nM, EC50W2 = 96.7 ± 56.3 ng/mL, EC50TM90-C2B = 55.5 
± 27.8 ng/mL), mefloquine (EC50K1 = 31 ± 18 nM, EC503D7 = 62 ± 31), atovaquone (EC50W2 = 0.574 ± 0.306 
ng/mL, EC50TM90-C2B = 7.54 ± 4.65 µg/mL) and dihydroartemisin (EC50W2 = 1.41 ± 0.29 ng/mL, EC50TM90-C2B = 
1.76 ± 0.12 ng/mL) are the internal controls for the in vitro anti-malarial activity assays. Podophyllotoxin is the 
internal control for the in vitro cytotoxicity assay with EC50 = 250 ± 10 nM against J774A.1. 
2.2.2.4 Role of Stereochemistry in Activity 
Pure stereoisomers of 2.1 were formed via the chiral auxiliaries. Table 2.1 already 
showed that the trans isomer was more active. As seen in Table 2.8, stereochemistry 
plays a large role in the activity of 1,4-dihydropyridines in P. falciparum. (-)-Trans-2.1 
is completely inactive to all four strains while its enantiomer (+)-trans-2.1 has activity in 
the picomolar range. The same trend is seen with the cis isomers. The (4R,7R)-2.1 
enantiomer is inactive while the (4S,7S)-2.1 enantiomer has double digit nanomolar 
activity against 3D7 and K1 and triple digit nanomolar activity against W2 and TM90-
C2B.  
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Table 2.8: Comparison of activities of 2.1 stereoisomers
a
 
 
Compound 
4,7-
Stereochemistry 
3D7 
EC50  n 
K1 
EC50  n 
W2 
EC50  n 
TM90-C2B 
EC50  n 
J774A.1 
EC50   
2.1 4S,7S >6000 >6000 2130 2110 n/d 
2.1 4R,7R 17 10.5 200 514 n/d 
2.1 (+)-trans <0.3 <0.3 18.1 49.1 n/d 
2.1 (-)-trans >6000 >6000 >5000 >5000 n/d 
aChloroquine (EC50K1 = 1360 ± 960 nM, EC503D7 = 48 ± 25 nM, EC50W2 = 96.7 ± 56.3 ng/mL, 
EC50TM90-C2B = 55.5 ± 27.8 ng/mL), mefloquine (EC50K1 = 31 ± 18 nM, EC503D7 = 62 ± 31), atovaquone 
(EC50W2 = 0.574 ± 0.306 ng/mL, EC50TM90-C2B = 7.54 ± 4.65 µg/mL) and dihydroartemisin (EC50W2 = 
1.41 ± 0.29 ng/mL, EC50TM90-C2B = 1.76 ± 0.12 ng/mL) are the internal controls for the in vitro anti-
malarial activity assays. Podophyllotoxin is the internal control for the in vitro cytotoxicity assay with 
EC50 = 250 ± 10 nM against J774A.1. 
 
2.2.2.5 Role of Stereochemistry on Solubility and Permeability 
Solubility at pH 7.4 was determined using Biomek FX lab automation workstation with 
pION µSOL evolution software as reported previously.
114
 Passive transcellular 
permeability was assessed in a standard parallel artificial membrane permeability assay 
(PAMPA) at pH 7.4. Solubilities of the four stereoisomers ranged from 0.2 µM for (+)-
trans-2.1 to 2.9 µM for (4S,7S)-2.1 (Table 2.9). Membrane permeabilities for all four 
stereoisomers were in a suitable range.  
Table 2.9: Comparison of solubilities and permeabilities of 2.1 stereoisomers
a
 
 
Compound 
4,7-
Stereochemistry 
Solubility pH 7.4 µM 
Permeability pH 7.4 
Pe 106 cm/s R% 
2.1 4R, 7R 1.3 1180 ± 130 80 ± 2 
2.1 4S, 7S 2.9 872 ± 105 85 ± 3 
2.1 (+)-trans 0.2 846 ± 102 86 ± 0 
2.1 (-)-trans 1.3 1110 ± 460 80 ± 4 
aAlbendazole (2.4 ± 0.8 μM, 352 ± 35 cm/s, 2.4 ± 0.8%), carbamazepine (91.8 ± 1.2 μM, 111 ± 30 
cm/s, 38 ± 4%), ranitidine HCl (81.1 ± 1.2 μM, 4 ± 1 cm/s, 4  ± 1%) and verapamil HCl (74.9 ± 1.7 
μM, 1950 ± 240 cm/s, 59 ± 12%) are the internal controls for the solubility and permeability assays. 
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2.3 Summary 
Thirty-three 1,4-dihydropyridine diastereomeric pairs were synthesized and the structure-
activity relationship studied. Twenty-nine of these derivatives contained a 6-position 
oxygen, with 2.31, 2.32, 2.52 and 2.53 having single and double digit nanomolar 
activities. This SAR study revealed some insightful information about the 1,4-
dihydropyridine substitution pattern (Figure 2.35). A few combinations would be 
interesting to synthesize to see how the activities combine. At the 4-position, a 4-chloro-
2-methylphenyl derivative could be expected to increase the activity. A 4-chloro-3-
methoxyphenyl at the 7-position can be tested to see how it compares with the 3,4-
dimethoxyphenyl substituent. 
 
Figure 2.35: Anti-malarial SAR of the 1,4-dihydropyridine  
Using the SAR from the 6-position oxygen derivatives, 6-methylene derivatives with 4-
(4-chlorophenyl) 2.59 and 2.60 were synthesized that displayed better activity than the 
original 4-(2-chlorophenyl) 2.1 derivative. 
Lastly, stereochemistry was revealed to play an important role in the activity of 2.1. One 
stereoisomer, (+)-trans-2.1, had subnanomolar activity. Another stereoisomer, (4S,7S)-
2.1, had nanomolar activity. The other two stereoisomers were inactive. 
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1,4-Dihydropyridines have been shown to have potential in the treatment of malaria. The 
performed SAR has given incredible insight for this chemotype. The high selectivity of 
these compounds between P. falciparum and human cells is an encouragement for their 
continued study. Based on the activities of the previous compounds it is recommended 
that in vivo studies are begun to study the efficacy of these compounds in mammals.  
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Chapter 3: Quinazolines as Anti-Leishmanials 
3.1 Chemistry of the Quinazoline Class 
Quinazolines are a class of compounds characterized by two fused six membered 
aromatic rings, a benzene and a pyrimidine. The electronics of the quinazoline system 
have two large dipoles, with increased electron density on the two nitrogens and electron 
deficiency on the 2- and 4-carbons (Figure 3.1).
115
  
 
Figure 3.1: Electronics of the quinazoline system 
Electronically, the quinazoline nitrogens act like electron-withdrawing nitro groups. This 
electron deficient property causes an activation of reactivity for halo-substituted 
quinazolines 3.A when the halogen is at the 2- or 4-position, causing nucleophilic 
aromatic substitutions to occur readily (Figure 3.2).
115-116
  
 
Figure 3.2: Reactivity of the 2,4-dichloroquinazoline 
The halogen at position 4 is more reactive than at position 2, allowing for reactions such 
as aminolysis to occur under minimal conditions at the 4-positon 3.B and then the 2-
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position 3.C with more vigorous conditions.
115-116
 Substitution of the 4-halogen with an 
amine again reduces the activity at the 2-position, as an electron-donating group is now 
directly attached to the system.  
3.2 Medicinal Importance of the Quinazoline Class 
The quinazoline class of compounds displays a wide range of biological activity. They 
have been shown in literature to have properties as anti-cancer, sedative-hypnotic, alpha 
blocker, anti-fungal, anti-inflammatory, anti-convulsant, anti-malarial, anti-mutagenic, 
anti-coccidial, anti-leukemic, CNS depressant, anti-leishmanial and anti-bacterial agents 
(Figure 3.3).
117
 Pandeya et al. showed moderate anti-bacterial and anti-fungal activity 
with Schiff bases of isatin containing quinazolinone derivatives.
118
 They tested the anti-
HIV properties of the compounds as well but did not find activity lower than the 
cytotoxicity ceiling. Gawad et al. tested 3-arylquinazolin-4(3H)-ones in a growth 
inhibition test against tumor cell lines and displayed results up to 80% inhibition of 
growth at 10 M.119 Fluorinated hydroquinazoline derivatives were reported by Ghorab 
et al. displaying anti-fungal activity with minimum inhibitory concentrations as low as 40 
g/mL against Aspergillus ochraceus, Penicillium chrysogenum, A. flavus and Candida 
albicans.
120
 Aly et al. reported 3-arylquinazolin-4(3H)-ones displaying anti-convulsant, 
analgesic, anti-fungal against Fuzarium species yet no anti-bacterial activity.
121
 2-
Styrlquinazolin-4(3H)-ones displayed up to 88% growth inhibition of L-1210 cell lines at 
1 g/mL in an anti-leukemic assay reported by Raffa et al.122 Werbel and Degnan 
reported the reduction of in vivo malarial and in vitro leukemia cell activity with amine 
substitution of quinazolin-2,4-diamine derivatives.
123
 Febrifugine derivatives were found 
to have anti-coccidial activity in an in vivo chicken assay reported by Ye et al., with 
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protection at 9 mg/kg.
124
 Kumar et al. tested mice and male albino rats for the anti-
inflammatory, analgesic and ulcerogenic activity of 2,3,6-trisubstitutedquinazolinones.
125
 
The in vivo properties were thought to be favorable with subcutaneous or intraperitoneal 
injections up to 100 mg/kg. Balakumar et al. showed imidazo[1,2-c]quinazoline 
derivatives with anti-inflammatory activity in the same range as indomethacin, a standard 
used for in vivo studies.
126
 Sedative-hypnotic and CNS depressant activities were reported 
by Jatav et al. in in vivo screens of rats and mice with 3-thiadiazol-2-styrylquinazolin-
4(3H)-one derivatives.
127
 Doxazosin is a quinazolin-2,4-diamine -adrenoreceptor 
blocker that is sold by Pfizer to treat hypertension.
128
As shown in the previous studies, 
numerous in vivo studies have been conducted with quinazoline derivatives. 
 
Figure 3.3: Biological role of quinazolines in the literature  
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3.2.1 Quinazolines in the Literature as Anti-Leishmanials 
Due to increased parasite resistance, cytotoxicity issues of current treatments, and long 
treatment regimens, new drugs are necessary to have an effective strategy for treating 
visceral leishmaniasis. Quinazolines are a class of compounds that have been studied and 
have shown potential as anti-leishmanials. Berman et al. reported a class of 2,4-
diaminoquinazolines 3.D with ED50 as low as 0.04 nM against L. major amastigotes in 
human monocyte-derived macrophages, however the development of this compound 
series was abandoned due to toxicity issues (Figure 3.4).
129
 Bhattacharjee et al. 3.E, Ram 
et al. 3.F, and Shakya and Gupta et al. 3.G and 3.H have also recently tested quinazolines 
as anti-leishmanials with activities below 100 ng/mL in some cases.
130
 This class of 
compound has been reported as being dihydrofolate reductase inhibitors, although 
another mechanism of action may be involved with Leishmania.
129, 131
 
 
Figure 3.4: Quinazolines shown to have anti-leishmanial activity 
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3.3 Anti-Leishmanial Testing 
Recently, we tested a small library of structurally diverse compounds, originally designed 
as potential anti-cancer probes, for anti-leishmanial activity in a L. mexicana axenic 
amastigote assay. Among this library were N
2
,N
4
-disubstituted quinazolines 3.1 and 3.2, 
which are structurally different from quinazoline series A-E. Anti-leishmanial testing of 
quinazolines 3.1 and 3.2 against L. mexicana axenic amastigotes revealed EC50 values in 
the single digit micromolar range, motivating us to investigate whether quinazolines 
structurally related to the hits 3.1 and 3.2 have potential to display potent anti-leishmanial 
activity (Figure 3.5).  Herein, we report a detailed structure-activity relationship (SAR) 
study focusing on the 2-position, the 4-position, and the quinazoline’s benzenoid ring. All 
compounds were initially examined in a L. donovani and L. amazonensis intracellular 
amastigote assay to preselect quinazoline candidates. Promising compounds have 
subsequently been tested for efficacy in a murine model of visceral leishmaniasis. 
 
Figure 3.5: Hit compounds 1 & 2 and SAR positions of quinazoline 
3.3.1 Synthetic Chemistry 
The compounds were synthesized following known procedures (Figure 3.6).
132
 
Commercially available anthranilic acids 3.I were cyclized with urea and the resulting 
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quinazoline-2,4-dione 3.J was reacted with phosphorous oxychloride to give the 2,4-
dichloroquinazoline 3.K. Substitution with amines occurred selectively at position 4 
yielding 4-amino-2-chloroquinazoline 3.L followed by substitution at position 2 to give 
the 2,4-diaminosubstituted quinazoline 3.M. In this synthetic sequence, only 4-amino-2-
chloroquinazoline 3.L and the final N
2
,N
4
-disubstituted quinazoline-2,4-diamine 3.M 
have been purified and characterized.  
 
Figure 3.6: Synthesis of N
2
,N
4
-disubstituted quinazoline-2,4-diamines 
3.3.2 In vitro Anti-Leishmanial Efficacy and Cytotoxicity 
All target compounds were tested against L. donovani and L. amazonensis intracellular 
amastigotes to identify molecules that are broadly active against these medically 
important Leishmania species. The testing involved murine peritoneal macrophages as 
host cells, since compounds with potential for clinical use must be able to penetrate the 
infected macrophage in a human host. Anti-leishmanial activity was determined in an 
assay using transgenic parasites expressing a β-lactamase gene as outlined previously.133 
Concentration response data for each compound was fitted by a nonlinear regression 
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model and the concentration that induces 50% inhibition was calculated as the effective 
concentration EC50 (L. donovani or L. amazonensis.). Additionally, cytotoxicity against 
the macrophage cell line J774A.1 was determined as the effective concentration EC50 
(J774A.1) and the selectivity index SI was calculated as the ratio of EC50 value for 
J774A.1 and the value for L. donovani (SI = EC50 (J774A.1)/EC50 (L. donovani)).  
3.3.2.1 Structure-Activity Relationship Studies.  
To validate and optimize the anti-leishmanial activity of N
2
,N
4
-disubstituted quinazoline-
2,4-diamines, two compound subseries were prepared and tested. The first subseries 
focused mainly on the optimization of the N
2
-
 
and N
4
-moieties (Table 3.1), whereas the 
second subseries was designed to investigate whether analogues being substituted at the 
quinazoline's benzenoid ring display improved anti-leishmanial activity (Table 3.2). In 
vitro antileishmanial potency of compounds against intracellular L. donovani
133b
 and L. 
amazonensis
132a
 parasites was measured using the colorimetric assay as described 
previously.  
Starting from hit compound 3.2, N
4
-furfuryl-analogues 3.3 and 3.4 were prepared in 
which the N
2
-iso-propyl group was replaced by a short trifluoroalkyl- or hydroxyalkyl-
group. While the 2,2,2-trifluoroethyl-substituted quinazoline 3.3 was slightly less potent 
than compound 3.2, alcohol 3.4 lost potency against L. donovani and L. amazonensis by a 
factor of 10 and >13, respectively. Testing of a small set of quinazoline-2,4-diamines 3.5-
3.9 with N
4
-monosubstituted or N
4
-disubstituted with alkyl groups differing in size and 
polarity did not identify a particular structural motif improving the potency over 3.2. 
Replacement of the furfuryl and iso-propyl groups in 3.2 by two benzyl or two n-butyl 
groups yielded quinazolines 3.10 and 3.11, of which both analogues were more potent 
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than reference 3.2. Bis-benzyl-substituted quinazoline 3.10 displayed EC50s of 667 nM 
against L. donovani and 1.41 μM against L. amazonensis, whereas analogue 3.11 was 
approximately twofold less potent in comparison to compound 3.10. Consequently, a 
following set of six quinazolines 3.12-3.17 was designed in which one of the 2- and 4-
positions was substituted by one benzyl amine, while the remaining position was 
derivatized with an aniline, n-butylamine, or methylamine. Interestingly, with the 
exception of the N
4
-benzyl-N
2
-methyl-quinazoline-2,4-diamine 3.12, all of these 
compounds demonstrated sub-micromolar EC50s against L. donovani. Among these six 
quinazolines tested, the N
2
-benzyl-quinazoline-2,4-diamines 3.15-3.17 appeared to be at 
least twofold more potent against L. donovani than the N
4
-benzyl counterparts 3.12-3.14 
suggesting that an N
2
-benzyl is more favorable than an N
4
-benzyl for anti-leishmanial 
activity. This observation is similar to previous results with quinazolines 3.2-3.11. 
Compound 3.15 was the most potent compound with an EC50 of 149 nM against L. 
donovani. For L. amazonensis, the set of 3.12-3.17 displayed a similar activity trend, with 
N
2
-benzyl-quinazolines 3.15 and 3.16 being the most potent compounds with 
submicromolar or single digit micromolar EC50s. 
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Table 3.1: SAR study focusing on 2- and 4-positions
a
 
 
Compound R1 R2 
L. donovani L. amazonensis 
 
J774A.1 
SI 
EC50   EC50   EC50   
3.2 
  
2.5 ± 0.4 3.7 ± 1.6 17 ± 6 6.8 
3.3 
 
 
3.6 ± 1.1 5.8 ± 2.3 23 ± 10 6.4 
3.4 
  
25 ± 18 > 50 > 33 > 1.3 
3.5 
 
 
3.7 ± 0.3 7.6 ± 3.2 > 33 > 8.9 
3.6 
  
4.3 ± 1.2 5.1 ± 0.9 20 ± 6 4.7 
3.7 
 
 
6.9 ± 1.8 20 ± 3 > 33 4.8 
3.8 
  
>50.0 > 50.0 n.d. n.d. 
3.9 
  
8.9 ± 1.0 19 ± 3 > 33 > 3.7 
3.10 
  
0.67 ± 0.27 1.4 ± 0.5 5.5 ± 1.4 8.2 
3.11 
  
1.8 ± 0.4 2.1 ± 1.1 5.4 ± 1.4 3.0 
3.12 
 
 
1.5 ± 0.5 13 ± 3 18 ± 8 12 
3.13 
  
0.65 ± 0.10 1.8 ± 0.2 5.1 ± 1.5 7.8 
3.14 
  
0.64 ± 0.10 2.6 ± 0.7 6.8 ± 0.2 11 
3.15 
 
 
0.15 ± 0.02 0.90 ± 0.27 15 ± 1 100 
3.16 
  
0.34 ± 0.12 1.4 ± 0.2 4.9 ± 1.3 14 
3.17 
  
0.26 ± 0.15 2.2 ± 0.3 5.2 ± 1.3 20 
aAmphotericin B is the internal control for the in vitro anti-leishmanial activity assay with EC50 = 40 ± 9 
nM against L. donovani and EC50 = 89 ± 16 nM against L. amazonensis. Podophyllotoxin is the internal 
control for the in vitro cytotoxicity assay with EC50 = 250 ± 10 nM against J774A.1. 
 
N
4-
Furfuryl-N
2
-iso-propyl-substituted quinazoline 3.2, with EC50s of 2.50 M against L. 
donovani and 3.71 μM against L. amazonensis, was considered to be well suited as the 
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key scaffold for a SAR study focusing on the benzenoid moiety of the quinazoline core. 
In a systematic approach following the Topliss operational scheme, compound 3.2 was 
mono-substituted with either a chlorine atom, a methyl group, or a methoxy group in the 
5-, 6-, 7-, and 8-positions to probe the benzenoid ring for steric and electronic effects.
134
 
Overall, substitution on the benzenoid ring provided compounds with EC50s in the single 
digit micromolar or sub-micromolar range against L. donovani. Among the chloro-
substituted subseries, 5- and 6-substituted analogues 3.18 and 3.19 were less potent by a 
factor of two or more compared to reference 3.2, while the 7- and 8-substituted 
quinazolines 3.20 and 3.21 displayed an activity on par with compound 3.2. In contrast, 
the majority of the methyl- and methoxy-substituted quinazolines demonstrated a modest 
potency improvement over quinazoline 3.2. For the methoxy-substituted quinazolines, 
potency increased according to substitutions in 8- < 7- < 5- ≈ 6-position, whereas a 
potency dependence in the order of 8- ≈ 6- < 7- ≈ 5-positions was observed for the 
methyl-substituted compounds. 7-Methoxy-quinazoline 3.28 with an EC50 of 740 nM 
against L. donovani was the most potent analogue of the compound subseries substituted 
at the benzenoid ring. In contrast, the testing of the benzenoid ring substituted 
quinazolines against L. amazonensis gave insight into a SAR, which differed from the 
one observed for L. donovani. 8-Methoxy-substituted quinazoline 3.29 was the only 
analogue which was marginally more potent than reference compound 3.2, whereas all of 
the other analogues were equally or less potent than quinazoline 3.2.  
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Table 3.2: Benzenoid substitution 
 
Compound R1 R2 R3 R4 
L. donovani L. amazonensis 
 
J774A.1 
SI 
EC50   EC50   EC50   
3.2 -H -H -H -H 2.5 ± 0.4 3.7 ± 1.6 17 ± 6 6.8 
3.18 -H -H -H -Cl 4.4 ± 1.3 18 ± 6 > 33 > 7.5 
3.19 -H -H -Cl -H 9.0 ± 3.7 23 ± 5 >100 > 11 
3.20 -H -Cl -H -H 2.6 ± 1.9 25 ± 4 > 33 > 13 
3.21 -Cl -H -H -H 2.3 ± 0.6 12 ± 3 25 ± 3 11 
3.22 -H -H -H -CH3 4.2 ± 2.1 4.4 ± 1.9 > 33 > 7.9 
3.23 -H -H -CH3 -H 0.83 ± 0.32 4.1 ± 1.2 > 33 > 40 
3.24 -H -CH3 -H -H 4.7 ± 2.5 15 ± 6 > 33 > 7.0 
3.25 -CH3 -H -H -H 0.95 ± 0.27 3.6 ± 1.5 20 ± 9 21 
3.26 -H -H -H -OCH3 3.2 ± 1.2 7.3 ± 2.5 30 ± 5 9.4 
3.27 -H -H -OCH3 -H 1.2 ± 0.5 10 ± 2 16 ± 2 13 
3.28 -H -OCH3 -H -H 0.74 ± 0.37 9.6 ± 3.0 14 ± 1 19 
3.29 -OCH3 -H -H -H 0.97 ± 0.26 2.7 ± 1.4 18 ± 6 19 
aAmphotericin B is the internal control for the in vitro anti-leishmanial activity assay with EC50 = 40 ± 9 nM 
against L. donovani and EC50 = 89 ± 16 nM against L. amazonensis. Podophyllotoxin is the internal control for 
the in vitro cytotoxicity assay with EC50 = 250 ± 10 nM against J774A.1. 
 
3.3.2.2 Cytotoxicity 
An important quality of the quinazolines is their selectivity to inhibit parasite growth over 
mammalian cells. Generally, the majority of the quinazolines 3.2-3.29 exhibited EC50s of 
20 μM or higher against J774A.1 (Tables 1 and 2). Quinazolines 3.18-3.20 and 3.22-3.24, 
whose benzenoid ring is substituted with one chloride or one methyl in 5-, 6- or 7-
position, were significantly less toxic than their reference 3.2. The quinazolines 
displaying potent anti-leishmanial activity, especially the N
2
-benzyl-quinazoline-2,4-
diamines 3.15-3.17, were shown to have respectable SI values of 10 and larger indicating 
that they are relatively selective, nontoxic chemotypes. Toxicity of compounds against 
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the murine macrophage cell line J774A.1 was conducted using the 3-(4,5)-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as previously 
described
135
 except that cells were incubated with compounds for 72 h. 
3.3.3 Mechanism of Action 
We investigated the possibility that quinazolines inhibit folate metabolism in the parasite. 
L. donovani axenic amastigotes and J774A.1 (mouse macrophage cell line) were adapted 
to grow in media deficient in p-aminobenzoic acid (PABA) and folic acid prior to 
susceptibility testing. Susceptibility to quinazolines, methotrexate, pyrimethamine, and 
miltefosine were assessed in the presence or absence of folinic acid (Figure 3.7). 
 
Figure 3.7: In vitro efficacy of quinazolines, methotrexate (MTX), pyrimethamine (PYR), 
and miltefosine (MILT) for axenic amastigotes of Leishmania donovani in the absence or 
presence of d,l-folinic acid (FNA) 
 The presence of folinic acid dramatically increased the EC50 values of each of the 
quinazolines as well as the methotrexate and pyrimethamine. For example, quinazoline 
3.23 was 6.4 fold less potent in the presence of 488 nM folinic acid than in completely 
deficient media. Conversely, efficacy of miltefosine was not affected by addition of 
folinic acid to the media. Interestingly, we saw no antagonism of activity of quinazolines 
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3.10, 3.12, 3.13, 3.15, 3.16 or 3.23 for the mammalian cell line (J774A.1) in the presence 
of folinic acid. For example, the EC50 of quinazoline 3.10 was 84.8 ± 2.2 μM and 84.2 ± 
2.8 μM in the presence or absence of 488 nM folinic acid, respectively. In contrast, the 
efficacy of methotrexate and pyrimethamine were antagonized significantly by folinic 
acid in J774A.1.  These results are consistent with the hypothesis that the quinazolines 
interfere with folate metabolism in L. donovani. 
3.3.4 Structure-Property Relationship Studies.  
In parallel to testing the compounds for anti-leishmanial activity in vitro, a structure-
property relationship (SPR) study focusing on log D, aqueous solubility, and permeability 
has been conducted with all compounds to assess potential physicochemical liabilities 
(Table 3.3). Log D3.0 and Log D7.4, the distribution coefficient between octanol and water 
at pH 3.0 and pH 7.4, were experimentally determined via a previously described HPLC-
based method.
136
 Solubility at pH 7.4 was determined using Biomek FX lab automation 
workstation with pION µSOL evolution software as reported previously and at pH 2.0 
using an in-house HPLC assay based on UV absorption.
114
 Passive transcellular 
permeability was assessed in a standard parallel artificial membrane permeability assay 
(PAMPA) at pH 7.4 and pH 4.0. Generally, the aqueous solubility, the distribution 
coefficient Log D, and the permeability of all quinazolines display a pH dependence 
(exemplified on Log D or permeability in Table 3.3). The permeability is enhanced at 
neutral pH while the aqueous solubility and Log D are better at lower pH ranges. 
However, since the aqueous solubility, the distribution coefficient, and the permeability 
are within the acceptable ranges (solubility > 20 M, Pe > 10 x 10-6 cm·s-1, 1 < Log D < 
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4), the quinazoline compound series is considered to be suitable for the development of 
bioavailable anti-leishmanial compounds. 
Table 3.3: Physicochemical properties of quinazolines 
Compound 
Solubility
a
 
Permeability Pe ·10
-6
 
(cm/s)
b 
Log D 
pH 7.4 pH 2.0 pH 7.4 pH 4.0 pH 7.4 pH 3.0 
3.2 ***** ***** 883 62.2 3.15 2.18 
3.3 *** ***** 979 67.7 4.20 2.02 
3.4 **** ***** 1130 26.4 2.19 1.48 
3.5 ***** ***** 780 19.7 3.19 2.40 
3.6 **** ***** 1480 28.8 3.02 2.06 
3.7 **** ***** 744 38.8 2.54 1.73 
3.8 **** ***** 783 112 4.69 3.56 
3.9 *** ***** 1120 72.3 3.13 1.64 
3.10 ** **** 383 312 3.82 2.82 
3.11 *** ***** 880 485 3.89 2.91 
3.12 ***** ***** n/d n/d 3.14 2.11 
3.13 *** ***** 1250 161 3.80 2.84 
3.14 * ** 1480 271 4.17 2.78 
3.15 *** ***** 1720 57.1 2.96 2.00 
3.16 *** ***** 1020 341 3.84 2.86 
3.17 * ***** 663 412 4.25 2.67 
3.18 ** ***** 1330 67.6 3.96 2.38 
3.19 **** ***** 1380 103 3.91 2.51 
3.20 **** ***** 1630 170 3.99 2.60 
3.21 *** ***** 1240 169 4.44 2.62 
3.22 **** ***** 666 45.9 3.55 1.57 
3.23 **** ***** 798 67.2 3.61 1.58 
3.24 **** ***** 789 67.2 3.63 1.55 
3.25 *** ***** 812 45.9 3.55 2.44 
3.26 **** ***** 1060 38.4 3.40 2.99 
3.27 **** ***** 1330 59.2 3.70 3.11 
3.28 ***** ***** 1010 80.2 3.58 2.95 
3.29 **** ***** 624 87.0 3.35 2.53 
a (*) for solubility ≤ 5 μM, (**) for 5 μM < solubility ≤ 10 μM, (***) for 10 μM < solubility ≤ 20 μM, (****) for 
20 μM < solubility ≤ 30 μM, (*****) for solubility ≥ 30 μM. n/d: not determined. b For the determination of the 
Pe values, the following internal controls were utilized: carbazepine pH 4.0 permeability Pe = 108·10-6 (cm/s) 
and pH 7.4  permeability Pe = 130·10-6 (cm/s); ranitidine·HCl pH 4.0 permeability Pe = 5.2·10-6 (cm/s) and pH 
7.4  permeability Pe = 2.2·10-6 (cm/s); verapamil·HCl pH 4.0 permeability Pe = 20.6·10-6 (cm/s) and pH 7.4  
permeability Pe = 1360·10-6 (cm/s). 
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3.3.5 In Vivo Anti-Leishmanial Efficacy Studies 
For the selection of the candidates for in vivo efficacy against L. donovani, only 
compounds which displayed submicromolar in vitro activity against L. donovani with a 
SI value greater than ten and a balanced combination of good physicochemical properties 
were chosen. Among the benzyl-substituted quinazolines 3.12-3.17,  3.15 and 3.16 
appeared to be the best candidates for in vivo evaluation due to their combination of 
potency, selectivity, and favorable physicochemical properties. From the compound 
subseries substituted at the benzenoid ring, the physicochemical properties were not 
discriminatory and hence compound 3.23 was chosen as a viable candidate due to its 
submicromolar EC50 against L. donovani as well as the outstanding SI value of this 
compound  (> 40). 
The three compounds mentioned above were dissolved in an appropriate vehicle (3.15 
and 3.23 dissolved in 0.5% methyl cellulose and 0.1% Tween80 in water, 3.16 dissolved 
in 45% (w/v) (2-hydroxypropyl)-β-cyclodextrin (HPβCD) solution) and administered to 
uninfected BALB/c mice intraperitoneally to determine a tolerated dose for in vivo 
efficacy studies. While 3.15 was well tolerated when given at 30 mg/kg ip for five 
consecutive days, 3.16 (slowed breathing) and 3.23 (hypoactivity) were toxic to animals 
when given at the same dosing regimen. Considering the toxicity of 3.16 and 3.23 when 
given at 30 mg/kg i.p., lower doses of these compounds were administered in subsequent 
in vivo efficacy studies in a murine visceral leishmaniasis model (Figure 3.8).  When 
tested at 5 × 15 mg/kg ip, 3.23 inhibited liver parasitemia by 37% compared to the 
vehicle control. However, 3.15 did not show significant anti-leishmanial efficacy when 
tested at 5 × 30 mg/kg i.p. There was also no significant difference in the parasite burden 
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between mice in the group treated with compound 3.16 (5 × 10 mg/kg i.p.) and the 
vehicle control group (P > 0.05). As expected, the 45% HPβCD vehicle used to solubilize 
3.16 itself resulted in 18% inhibition of liver parasitemia, consistent with a previous 
report.
133b
 
The in vivo antileishmanial efficacy of compounds was evaluated in a murine model of 
visceral leishmaniasis by the general method described earlier
132a
 with minor 
modifications. Briefly, BALB/c mice were inoculated with LV82 promastigotes on day 0, 
and then weighed and marked individually on day 6 in order to calculate the volume of 
solution to be administered to each mouse. In these studies, 45% (w/v) (2-
hydroxypropyl)-β-cyclodextrin (HPβCD) vehicle was used to formulate 3.16 and 0.5% 
methyl cellulose/0.1% Tween80 in water (MC) was used to dissolve 3.15 and 3.23; all 
compounds and vehicles were administered intraperitoneally. After 5 consecutive days of 
treatment from days 7 to 11, animals were sacrificed on day 14. Liver smear slides from 
each animal were made and stained, and the liver parasitemia expressed in Leishman-
Donovan units (LDU) was determined by microscopy.
132a
 The efficacy of each 
compound was calculated according to the method published previously.
132a
 
Results are presented as the liver parasitemia (LDU) for each mouse (♦) and the average 
LDU in each group (-) determined by microscopy (n = 4). (A), LDU for mice treated with 
3.16 and 3.23; (B), LDU for mice treated with 3.15. All treatments were given by the i.p. 
route. Compounds 3.15 and 3.23 were dissolved in 0.5% methyl cellulose and 0.1% 
Tween80 (MC), while compound 3.16 was dissolved in 45% (w/v) (2-hydroxypropyl)-β-
cyclodextrin solution (HPβCD).  (*):  p < 0.05, compared with untreated control. 
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Figure 3.8: In vivo efficacy of quinazolines against LV82 in L. donovani infected 
BALB/c mice.   
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3.3.6 Pharmacokinetics of 3.16 and 3.23 
Pharmacokinetic studies were conducted to determine the systemic and target tissue 
exposures of 3.16 and 3.23. The mean plasma and tissue concentration–time profiles of 
3.16 and 3.23 after p.o. and i.p. administration are shown in Figure 3.9 and Figure 3.10, 
respectively. The relevant pharmacokinetic outcomes are listed in Table 3.4. After p.o. 
administration at 100 µmol/kg (or approximately 30 mg/kg), both compounds were 
absorbed from the gastrointestinal tract of mice and plasma concentration reached a Cmax 
of 0.44 and 0.25 μM for 3.16 and 3.23, respectively.  
 
Figure 3.9: Plasma (open circles) and tissue (squares for liver and triangles for spleen) 
concentration-time profiles after p.o. (A) and i.p. (B) administration of 16 in mice at a 
dose level of 100 μmol/kg (~30 mg/kg) 
Symbols and error bars in Figure 3.9 and Figure 3.10 represent the mean and standard 
error of triplicate determinations, except those labeled with asterisks where only one or 
two determinations were obtained due to sample loss. 3.23 was below the detection limit 
(0.1 μM) in the liver and spleen 12 and 24 h after i.p. administration. 
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The systemic and tissue exposure of 3.16 (AUC and Cmax) were considerably greater than 
those of 3.23 (Table 3.4). After i.p. administration, plasma concentration reached a Cmax 
of 5.2 and 2.7 μM for 3.16 and 3.23, respectively, before decreasing rapidly in the first 4 
h, followed by a slower elimination process until 24 h. The rapid decline in plasma 
concentration was likely due to extensive tissue redistribution after absorption, as 
indicated by the high target tissue concentrations. The plasma and tissue exposures after 
i.p. administration were markedly greater than those after p.o. administration (Table 3.4), 
suggesting significant first-pass metabolism and/or partial gastrointestinal absorption 
after oral administration of 3.16 and 3.23.  
Table 3.4: Pharmacokinetic outcomes of 3.16 and 3.23 after p.o. and i.p. administration to 
mice 
  Outcomes 
p.o. i.p. 
plasma liver spleen plasma liver spleen 
16 
Cmax (μM) 0.44 15.8 7.0 5.21 148 163 
Tmax (h) 4 1 1 1 1 1 
AUClast
a
 (μM•h) 7.8 110 68 11 500 620 
t1/2 (h) NC
b
 ND
c
 ND 20 ND ND 
Mic t1/2
d
 (min) 27 
23 
Cmax (μM) 0.25 5.2 0.9 2.67 48 45.8 
Tmax (h) 1 1 1 1 1 1 
AUClast
a
 (μM•h) 2.5 29 7.4 4.6 42 71 
t1/2 (h) 24 ND ND 5.4 ND ND 
Mic t1/2
d
 (min) 9.4 
a AUC(0-24h) was calculated for plasma using noncompartmental analysis, whereas AUC(1-24h) was calculated for 
tissues using trapezoid rule. AUClast, AUC from the time of dose to the last measurable concentration; Cmax and Tmax, 
maximum concentration and time to reach Cmax; t1/2, terminal half-life. 
b NC, not calculable due to lack of a data point.   
c ND, not determined. d In vitro mouse liver microsomeal half-life. 
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The terminal elimination half-life ranged from 5 to 20 h. Minor reversible overt toxicity 
(hypoactivity) was observed after i.p. administration of 3.16, however more severe 
toxicity was observed, unexpectedly, after a single i.p. administration of 3.23, which 
warranted euthanization of some mice within 15 min post dose. As efficacy was 
evaluated at lower doses than 30 mg/kg to avoid toxicity and dose linearity for 
pharmacokinetic outcomes were unknown, it is not possible to directly correlate drug 
exposure with anti-leishmanial activity in mice. In addition, it is worth pointing out that 
the terminal half-life of 3.23 after i.p. administration was considerably shorter than that 
after p.o. administration (5 h vs. 20 h; Table 3.4), and the liver concentration of 3.23 was 
detectable at 12 and 24 h after p.o. administration, whereas it was below detection limit 
after i.p. administration (Figure 3.10). These observations suggest flip-flop 
pharmacokinetics, where the rate of gastrointestinal absorption is slower than the rate of 
elimination due to dosage formulations (e.g. sustained-release), excipients, physicological 
factors (e.g. intestinal mobility and pH), and/or drug characteristics.
137
 The dramatic 
decrease (~12-fold) in the permeability of 3.23 from neutral to acidic pH (Table 3.3) 
could contribute to the slowed absorption of this compound in the upper gastrointestinal 
tract. In contrast, the permeability of 3.16 decreased only 3-fold from neutral to acidic pH 
(Table 3.3). Furthermore, 3.23 was metabolized quickly in the mouse liver microsomes 
(t1/2 = 9.4 min; Table 3.4), suggesting that it is possible that the rate of elimination was 
greater than the rate of gastrointestinal absoption for 23.  
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Figure 3.10: Plasma (open circles) and tissue (squares for liver and triangles for spleen) 
concentration-time profiles after p.o. (A) and i.p. (B) administration of 23 in mice at a 
dose level of 100 μmol/kg (~30 mg/kg) 
3.3.7 Summary 
N
2
,N
4
-disubstituted quinazoline-2,4-diamines 3.1 and 3.2 were found to display anti-
leishmanial activity in the single digit micromolar range.  Subsequently a total of 28 
molecules have been synthesized systematically by varying the substitutions in the 2-, 4-, 
5-, 6-, 7-, and/or 8-positions. All quinazolines have been tested with the aim to further 
optimize hit compounds 3.1 and 3.2 and to conduct a detailed SAR study against L. 
donovani and L. amazonensis. The most potent activities with EC50s in the 
submicromolar range against L. donovani were obtained with quinazoline-2,4-diamine 
scaffolds bearing either a N
2
-benzyl-N
4
-alkyl/phenyl or a N
2
-ispropyl-N
4
-furfuryl 
substituent combination. Furthermore, although the benzenoid ring of the quinazoline-
2,4-diamine scaffold has been identified to play a secondary role for efficacy, 
quinazolines substituted at the 5- or 6-position with one methyl or one methoxy group 
have also been identified to possess submicromolar EC50s against L. donovani. The best 
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quinazolines were shown to display cytotoxicity against the macrophage cell line 
J774A.1 at 10 M or higher concentrations yielding SI values larger than 10. In addition, 
assessment of key physicochemical properties confirmed that the quinazoline's aqueous 
solubility, distribution coefficient, and passive transcellular permeability were in 
acceptable ranges. These promising results led to efficacy testing of the lead compounds 
3.15, 3.16 and 3.23 in an in vivo murine visceral leishmaniasis model. While compounds 
3.15 and 3.16 did not have activity translate from in vitro to in vivo, quinazoline 3.23 
reduced parasitemia by 37% when 15 mg/kg/day were given via the intraperitoneal route 
for five consecutive days. Pharmocokinetic studies of compound 3.23 revealed a 
maximum plasma concentration that was threefold higher than the EC50 and a terminal 
half-life of 5 hours after i.p. administration. Thus, the observed potencies of frontrunner 
compounds 3.15, 3.16 and 3.23 in conjunction with favorable physicochemical and 
pharmacokinetic properties make N
2
,N
4
-disubstituted quinazoline-2,4-diamines a suitable 
platform for the future development of anti-leishmanial agents. 
3.4 Additional Testing 
Following the initial study concluding with in vivo data showing a reduction of 
parasitemia by 37%, a terminal half-life of 5 hours after i.p. administration and a plasma 
Cmax 3.25 times the L. donovani EC50 for compound 3.23, an additional twenty-nine 
compounds were synthesized with the hopes of improving the in vivo efficacy. These 
compounds mostly carried aromatic N
2
- and/or N
4
- substituents as these were the 
substituents that showed the highest activity in the previous study. A small sampling of 
N
2
,N
4
 dialkyl substitutions were also included to see if a broader sampling would show 
activity.  
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3.4.1 Structure-Activity Relationships 
3.4.1.1 Structure-Activity Relationship of N
2
- or N
4
- Alkyl with N
2
- or N
4
- Alkyl/Aryl 
As seen previously in Table 3.1, dialkyl substitution of the quinazolin-2,4-diamine 
resulted in compounds with single digit micromolar activity against intracellular L. 
donovani amastigotes (Table 3.5, compounds 3.30-3.35, 3.37). N
4
- phenyl or benzyl with 
N
2
-isopropyl resulted in compounds 3.34 and 3.35 with activities at 2 M, while N4-
furfuryl-N
2
-methyl 3.36 lost all potency. Another N
4
-furfuryl compound, 3.38 with N
2
-
cyclopentyl, also lost all potency whereas the N
2
-cyclohexyl derivative displayed single 
digit micromolar activity. The only compound from this set displaying submicromolar 
activity was the N
2
-benzyl 3.41, the N
4
-isopropyl derivative of compound 3.15 from 
Table 3.1. Replacing the N
4
-methyl of 3.15 with N
4
-isopropyl resulted in a drop of 
activity from 150 nM to 380 nM, but the cytotoxicity stayed in the same range at 14 M.  
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Table 3.5: N
2
- or N
4
- alkyl with N
2
- or N
4
- alkyl/aryl substitutions 
 
Compound R1 R2 
L. donovani J774A.1 
SI 
EC50   EC50   
3.30 
  
6.3 ± 1.9 n/d  
3.31 
  
6.1 ± 2.8 n/d  
3.32 
 
 
2.2 ± 0.5 n/d  
3.33 
  
8.9 ± 0.1 n/d  
3.34 
  
1.9 ± 0.2 n/d  
3.35 
  
2.0 ± 0.1 n/d  
3.36 
  
>25 n/d  
3.37 
 
 
4.4 ± 1.2 n/d  
3.38 
  
>25 n/d  
3.39 
  
4.0 ± 2.5 n/d  
3.40 
 
 
12 ± 9 n/d  
3.41 
  
0.38 ± 0.09 14 ± 1 37 
3.42 
  
20 ± 5 n/d  
3.43 
  
11 ± 3 n/d  
3.4.1.2 Structure-Activity Relationship of N
2
,N
4
-Diaryl Derivatives 
The diarylquinazolin-2,4-diamines generally had activity in the single digit micromolar 
or triple digit nanomolar range, with the exception of the N
2
-furfuryl derivative 3.44 
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(Table 3.6). Derivatives of compound 3.10 having benzyl substitutions at the para 
position with chloro, methyl or methoxy at N
2
 and/or N
4
 had activities between 0.4 and 6 
M with selectivity indexes around ten. The most active derivatives 3.46 and 43.7 were 
substituted with N
2
-4-chlorobenzyl and N
4
-4-methylbenzyl respectively, with a benzyl on 
the opposite amine. Compounds 3.49 and 3.52 were disubstituted with N
2
,N
4
-di(4-
methylbenzyl) and N
2
,N
4
-di(4-methoxybenzyl), respectively, and had potencies above 1 
M. 
Table 3.6: N
2
,N
4
-diaryl derivatives 
 
Compound R1 R2 
L. donovani J774A.1 
SI 
EC50   EC50   
3.44 
 
 
14 ± 6 n/d  
3.45 
  
0.82 ± 0.23 8.4 ± 0.5 10 
3.46 
  
0.61 ± 0.12 5.8 ± 0.8 9.5 
3.47 
  
0.39 ± 0.16 4.8 ± 2.1 12 
3.48 
  
0.89 ± 0.10 6.9 ± 0.5 7.8 
3.49 
  
1.1 ± 0.5 n/d  
3.50 
  
2.5 ± 0.2 n/d  
3.51 
  
0.72 ± 0.10 6.8 ± 0.4 9.4 
3.52 
  
6.0 ± 2.9 n/d  
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3.4.1.3 Structure-Activity Relationship of N
2
,N
4
-Diaryl Derivatives with Backbone 
Substitution 
Derivatives of compound 3.15 were made with 6-methoxy, 6-chloro or 7-chloro 
derivation (compounds 3.53-3.55, table 3.7). The 6-methoxy derivative, 3.53, was the 
only compound of the three to have submicromolar activity, although with a modest 
selectivity index of 14. Three 7-chloro derivatives of 3.10 were also made with all three 
having activities less than 0.5 M (compounds 3.56-3.58). The trichloro 3.58 displayed 
the highest potency at 260 nM with the monochloro 3.56 next with 370 nM and a 
selectivity index of 38. 
Table 3.7: 6- and 7-substituted derivatives 
 
Compound R1 R2 R3 
L. donovani J774A.1 
SI 
EC50   EC50   
3.53 
 
 
6-MeO 0.35 ± 0.06 4.8 ± 2.2 14 
3.54 
 
 
6-Cl 2.5 ± 0.3 n/d  
3.55 
 
 
7-Cl 1.4 ± 0.2 9.7 ± 4.0 6.9 
3.56 
  
7-Cl 0.37 ± 0.8 14 ± 1 38 
3.57 
  
7-Cl 0.26 ± 0.15 n/d  
3.58 
  
7-Cl 0.47 ± 0.05 5.1 ± 1.0 11 
 
3.4.2 Structure-Property Relationship Studies 
A structure-property relationship study was conducted for the new compounds as 
described for the previous compounds (Table 3.8). As can be seen in the lower half of the 
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table, the aryl substituted quinazolines have lower aqueous solubility and membrane 
permeability. 
Table 3.8: Physicochemical properties of quinazolines
 
Compound 
Solubility
a
 
Permeability Pe ·10
-6
 
(cm/s)
b 
Log D 
pH 7.4 pH 7.4 pH 4.0 pH 7.4 
3.30 *** 1490 13.6 2.45 
3.31 *** 1300 421 3.04 
3.32 *** 1190 42.1 3.14 
3.33 **** 744 38.8 n/d 
3.34 **** 1790 124 3.62 
3.35 **** 1340 159 3.50 
3.36 **** 744 4.51 2.61 
3.37 *** 1690 22.8 2.88 
3.38 **** 2090 116 3.54 
3.39 **** 854 176 4.18 
3.40 **** 788 46.1 4.66 
3.41 **** 436 71.1 3.54 
3.42 *** 963 10.5 2.59 
3.43 *** 543 n/d 3.23 
3.44 ** 288 72.2 3.25 
3.45 n/d n/d n/d n/d 
3.46 * n/d n/d n/d 
3.47 **** 854 67.3 n/d 
3.48 * 1070 160 n/d 
3.49 * 1 4 n/d 
3.50 * 1350 246 n/d 
3.51 * 1750 415 n/d 
3.52 * 441 14.6 n/d 
3.53 n/d n/d n/d n/d 
3.54 n/d n/d n/d n/d 
3.55 n/d n/d n/d n/d 
3.56 * n/d 153 n/d 
3.57 * 0.3 n/d n/d 
3.58 * 0.5 n/d n/d 
a (*) for solubility ≤ 5 μM, (**) for 5 μM < solubility ≤ 10 μM, (***) for 10 μM < 
solubility ≤ 20 μM, (****) for 20 μM < solubility ≤ 30 μM, (*****) for solubility ≥ 
30 μM. n/d: not determined. b For the determination of the Pe values, the following 
internal controls were utilized: carbazepine pH 4.0 permeability Pe = 108·10-6 (cm/s) 
and pH 7.4  permeability Pe = 130·10-6 (cm/s); ranitidine·HCl pH 4.0 permeability 
Pe = 5.2·10-6 (cm/s) and pH 7.4  permeability Pe = 2.2·10-6 (cm/s); verapamil·HCl 
pH 4.0 permeability Pe = 20.6·10-6 (cm/s) and pH 7.4  permeability Pe = 1360·10-6 
(cm/s). 
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3.4.3 Pharmacokinetics of 3.41 and 3.46 After Intraperitoneal Administration in Mice 
Pharmacokinetic studies were conducted to determine the systemic and target tissue 
exposures of 3.41 and 3.46. The mean plasma and tissue concentration–time profiles of 
3.41 and 3.46 after i.p. administration are shown in Figure 3.11.  
 
Figure 3.11: Plasma and tissue concentration-time profiles after 10 mg/kg i.p. 
administration of 3.41 and 3.46 
The relevant pharmacokinetic outcomes are listed in Table 3.9. After i.p. administration, 
plasma concentration reached a Cmax of 2.15 and 1.40 μM for 3.41 and 3.46, respectively. 
The rapid decline in plasma concentration was likely due to extensive tissue 
redistribution after absorption, as indicated by the high target tissue concentrations 
(Figure 3.11). The tissue concentration of 3.41 drastically declined over 12 hours while 
the decline was much slower for 3.46 with 10 μM concentrations still found at 12 hours 
in the liver and spleen. The terminal elimination half-life was 2 hours and 9 hours for 
3.41 and 3.46, respectively.  
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Table 3.9: Pharmacokinetic outcomes of 3.41 and 3.46 after 10 mg/kg i.p. administration 
to mice 
 
Outcomes 
i.p. 
plasma 
3.41 
Cmax (μM) 2.15 
Tmax (h) 0.25 
AUClast (μM•h) 7.14 
t1/2 (h) 2.05 
3.46 
Cmax (μM) 1.40 
Tmax (h) 0.50 
AUClast (μM•h) 15.7 
t1/2 (h) 9.31 
 
3.4.4 In Vivo Anti-Leishmanial Efficacy Studies of Compounds 3.28, 3.41 and 3.46 
For the selection of the candidates for in vivo efficacy against L. donovani, only 
compounds which displayed submicromolar in vitro activity against L. donovani were 
chosen, with the rationale for selections based on other data we had acquired. Compound 
3.28 was reintroduced because of its best-in-class activity among the original benzenoid 
substitutions and excellent SPR data. Compound 3.41 was chosen as an analogue to 3.15. 
It was believed that 3.15 lost all activity in the in vivo assay due to the presence of the N
4
-
methyl substitution and enzymatic demethylation in vivo. 3.41, with the N
4
-isopropyl 
substitution, was hoped to circumvent this problem and maintain excellent activity in the 
murine model. Compound 3.46, with admittedly poor SPR data, was chosen based on the 
high concentration-time profiling found during the pharmacokinetic study.  
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The three compounds 3.28, 3.41 and 3.46 were dissolved in a vehicle consisting of 5% 
DMSO, 50% PEG 400, 10% ethanol and 35% water. When tested at 5 × 10 mg/kg ip, 
3.28 inhibited liver parasitemia by 17%, 3.41 inhibited liver parasitemia by 24%, and 
3.46 inhibited liver parasitemia by 12% compared to the vehicle control (Figure 3.12).  
 
Figure 3.12: In vivo efficacy of quinazolines in L. donovani infected BALB/c mice 
3.4.5 Summary 
Following the original study of 28 synthesized molecules with various substitutions in the 
2-, 4-, 5-, 6-, 7-, and/or 8-positions, an additional 29 were synthesized and tested. The 
most potent activities with EC50s in the submicromolar range against L. donovani were 
obtained with quinazoline-2,4-diamine scaffolds bearing either a N
2
,N
4
-dibenzyl or a N
2
-
benzyl-6-methoxy-N
4
-methyl substituent combination. Enhancement of activity was 
encountered with quinazolines substituted at the 7-position with a chloro group. The best 
quinazolines were shown to display SI values larger than 10 with few compounds having 
cytotoxicity values of 10 M or higher concentrations against the macrophage cell line 
0 
500 
1000 
1500 
2000 
2500 
3000 
3500 
4000 
Untreated 
Control  
Miltefosine 10 mg/kg 
3.28 
10 mg/kg 
3.41 
10 mg/kg 
3.46 
Le
is
h
m
an
-D
o
n
o
va
n
 U
n
it
s 
(L
D
U
) 
Mouse 1 
Mouse 2 
Mouse 3 
Mouse 4 
Average 
103 
 
J774A.1. These promising results led to efficacy testing of the lead compounds 3.28, 3.41 
and 3.46 in an in vivo murine visceral leishmaniasis model. Of the three, quinazoline 3.41 
reduced parasitemia the most by 24% when 10 mg/kg/day were given via the 
intraperitoneal route for five consecutive days. Pharmocokinetic studies of compound 
3.41 revealed a maximum plasma concentration that was 2.3 times higher than the EC50. 
For compound 3.46, the concentration was 5.7 times higher than the EC50. 
The observed potencies of frontrunner compounds 3.28, 3.41 and 3.46 in conjunction 
with the earlier data from 3.15, 3.16 and 3.23 make N
2
,N
4
-disubstituted quinazoline-2,4-
diamines a possible platform for the future development of anti-leishmanial agents. In 
vivo efficacy needs to be improved in order for a hit to become a lead and this may occur 
via the study of new substituents. Complex secondary amines will be looked at as well as 
some of the untested compounds from this study, such as 3.47, that have displayed decent 
activities with better physicochemical properties.  
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Chapter 4: Quinazolines and the ESKAPE Pathogens 
4.1 Quinazolines as Anti-Bacterial Agents 
Quinazolines are a class of compounds that have been studied and have shown potential 
as anti-bacterial agents. Huband et al. have reported substituted quinazolin-2,4-dione 4.A 
as bacterial gyrase and topoisomerase inhibitors (Figure 4.1).
138
 They report a minimum 
inhibitory concentration against 90% of the tested strains (MIC90) of 0.5 µg/mL versus 
staphylococci, 0.06 µg/mL versus streptococci, 2 µg/mL versus enterococci, and 0.5 
µg/mL versus Moraxella catarrhalis, Haemophilus influenzae, Listeria monocytogenes, 
Legionella pneumophila and Neisseria species. Compound 4.A was used in a S. aureus in 
vivo murine acute lethal infection model, where an oral dose of 2.5 ± 1.8 mg/kg of 4.A 
was found to protect 50% of mice infected with MRSA strain SA-1417. 
Indolo[1,2-c]quinazoline 4.B and its analogues have been shown to have anti-bacterial 
and anti-fungal activity by Rohini et al. (Figure 4.1).
139
 These compounds had zones of 
inhibition (ZOI) in Kirby-Bauer tests, and their MICs were evaluated against Gram-
positive and negative bacteria, including Staphylococcus aureus, Bacillus subtilis, 
Streptococcus pyogenes, Salmonella typhimurium, Escherichia coli and Klebsiella 
pneumonia, and also against the fungi Aspergillus niger, Candida albicans and 
Trichoderma viridae. 4.B had MICs between 2 and 5 µg/mL against all tested bacteria 
and between 2 and 10 µg/mL for fungal isolates.  
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Figure 4.1: Quinazolines with reported anti-bacterial activity 
Mycobacterial growth inhibition and dihydrofolate reductase inhibition was reported by 
DeGraw et al. with a series of 2,4-diaminoquinazolines 4.C (Figure 4.1).
140
 An MIC of 
1.8 µM was reported for 4.C and a marked synergistic effect was found with 
diaminodiphenyl sulfone. Although activity was found with Mycobacterium, 4.C was 
found to be inactive against Staphylococcus aureus, Enterococcus faecalis, 
Corynebacterium acnes, Pseudominas aeruginosa, Erysipelothrix insidiosa, Escherichia 
coli, Proteus vulgaris and Salmonella chloraesuis. 
In vitro activity against E. coli, S. aureus and K. pneumonia was seen from 4.D at MICs 
of 2 µM, 12 µM and 12 µM, respectively, as reported by Kung et al. (Figure 4.1).
141
 In an 
in vivo murine model, 4.D afforded a 40% survival rate when injected subcutaneously at 
100 mg/kg in mice infected with K. pneumonia. 
Gottasová et al. reported the in vitro activity of 4-aniloquinazoline 4.E against B. subtilis 
and S. aureus (Figure 4.1).
142
 An MIC of 10 µg/mL and an EC50 of 0.8 µg/mL for 4.E 
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was found against S. aureus. 4.E also had an MIC of 1 µg/mL and an EC50 of 0.7 µg/mL 
in assays using B. subtilis. 
4.2 Quinazolin-2,4-Diamine Activity Against Methicillin-Reisistant Staphylococcus 
aureus 
Recently, we tested a small library of quinazolines, structurally different from previously 
reported antibacterial quinazolines and originally designed as potential anti-leishmanials, 
for anti-bacterial activity. The results were promising as several compounds had zones of 
inhibition against methicillin-resistant Staphylococcus aureus (MRSA) in Kirby-Bauer 
tests. The Kirby-Bauer test is an introductory assay that allows for the quick 
identification of compounds that inhibit the growth of bacteria. A larger library was then 
tested and minimum inhibitory concentrations (MICs) were determined for those 
compounds having zones of inhibition. Herein, we report a detailed structure-activity 
relationship (SAR) study focusing on the 2-position, the 4-position, and the quinazoline’s 
benzenoid ring. Furthermore, we report the selection process leading to frontrunner 
compounds displaying low mutation frequencies and promising in vivo efficacy in murine 
models of infection. 
 
Figure 4.2: Positions of the quinazoline ring 
4.2.1 Testing of Quinazolines via Kirby-Bauer Assays 
Assessment of the quinazolin-2,4-diamine structure shows three locales for substitution 
patterns: N
2
-substitution, N
4
-substitution, and benzenoid substitution at positions C5-8 
107 
 
(Figure 4.2). Initial studies focused on the amine substitutions as shown in Table 4.1. 
Based on Kirby-Bauer assays, zones of inhibitions were determined. S. aureus CBD-635 
was struck out onto plates and incubated over night.  A single colony was used to 
inoculate broth and again allowed to grow overnight.  The overnight culture was diluted 
1:1000 into 5 mL of molten overlay agar and mixed, before being used to inoculate 
growth plates.  After plates were allowed to dry, 3 sterile filter disks were added per plate 
and then inoculated with 10 µL of test compound.  The stock concentration for each test 
compound was 5 mg mL
-1
 suspended in DMSO.  Bacterial plates were incubated for 24 
hours and zones of inhibition (ZOI) were measured in millimeters, with the assay being 
performed in triplicate. 
First, a subset of N
2
,N
4
-substituted quinazolines were tested, in which N
4
 was modified by 
a furfuryl moiety, while the N
2
-group was varied (Table 4.1). Quinazolines 4.1 and 4.2 
with a N
2
-methyl or N
2
-ethyl did not have ZOIs in the Kirby-Bauer assays. Branched 
alkyl groups on N
2
 furnished compounds 4.3 and 4.4 displaying inhibition while 
unbranched polar substituents in 4.5 and 4.6 lacked any activity. Cycloalkyl groups on N
2
 
varied in potency based on size: N
2
-cyclopropyl and N
2
-cyclobutyl quinazolines 4.7 and 
4.8 were inactive while analogues 4.9 and 4.10 with a N
2
-cyclopentyl and a N
2
-
cyclohexyl respectively created ZOIs. Next, compounds were tested with a furfuryl group 
at N
2
. Quinazoline 4.11 with N
4
-methyl was active while derivative 4.12 with a polar 
alcohol functionality remained inactive. Conclusions from this set showed that when a 
furfuryl was substituted at N
4
 activity would be seen when a bulky alkyl substituent was 
at N
2
 while small substituents were tolerated at N
4
 with N
2
 furfuryl. 
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A second subset of quinazolines was prepared to probe whether antibacterial activity can 
be improved via steric and electronic effects on the quinazoline benzenoid ring (Table 
4.2). N
4
-furfuryl-N
2
-isopropyl-substituted quinazoline 4.3 was selected as a reference 
compound, to which analogues 4.13-4.24 were compared with mono-substitution at 
positions C5-C8 with either a chloro, a methyl or a methoxy group. Quinazolines 4.13-
4.16 with one chloro substitutent suppressed the growth of bacteria. The analogues 4.17-
4.24 substituted with a methyl or a methoxy group were less potent with inhibition of 
growth observed in 25% and 50% of the samples, respectively. The trend noted for this 
set are that chloro- substitution is well tolerated while methoxy- is less so and methyl- is 
even less. 
With the idea to reduce the aromaticity, a subset of compounds was designed to test 
whether N
2
- and N
4
-residues rich in sp
3
-hybridized carbons are tolerated without 
compromising activity (Table 4.3). Analogues 4.25-4.40 were synthesized in which one 
of the two N
2
,N
4
-substitutents was a methyl, an isopropyl, or a 2-hydroxyethyl group, 
whereas the other consisted of a branched, an unbranched, or a saturated cycloalkyl 
moiety. None of these analogues were particularly active with the exceptions of the N
2
-
cyclopentyl-N
4
-isopropyl derivative 4.32 and N
4
-cyclohexyl-N
2
-isopropyl derivative 4.38, 
which both inhibited bacterial growth.  
 
A final focus was compounds with aromatic substitution (Table 4.4). Analogues 4.41-
4.54, bearing phenyl and/or benzyl derivation at N
2
 and/or N
4
 were successful in 
inhibiting the growth of S. aureus in Kirby-Bauer tests. 
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4.2.2 Minimum Inhibitory Concentration Assays 
After the identification of active compounds by Kirby-Bauer testing, the minimum 
inhibitory concentration (MIC) for these compounds was assessed to provide a more in-
depth structure-activity relationship. The minimum inhibitory concentrations (MIC) were 
determined for compounds which displayed antimicrobial activity against S. aureus 
CBD-635.  Broth cultures were prepared as described above.  These overnight cultures 
were diluted 1:1000 into fresh media and 200 µL was transferred to a sterile 96-well 
plate.  Relevant concentrations of test compounds were applied to each well and samples 
were mixed by pipetting before being incubated at 37°C overnight.  MICs were 
determined by visual inspection for the minimum concentration of drug that produced no 
bacterial growth (as determined by a lack of turbidity).  The assay was performed in 
triplicate to verify MICs. 
The N
2
-isopropyl derivative 4.3 is more active than the N
2
-tert-butyl 4.4 derivative (Table 
4.1). N
2
-cyclopentyl 4.9 and N
2
-cyclohexyl 4.10 display similar MICs and are 
comparable to the isopropyl. N
4
-isopropyl derivative 4.12 had an MIC ten times lower 
than the N
4
-methyl 4.11, with MICs of 35 and 390 , respectively.  
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Table 4.1: SAR of N-alkyl-N-furfurylquinazolin-2,4-diames 
        
Compound Structure ZOI 
(mm) 
MIC 
( 
Compound Structure ZOI 
(mm) 
MIC 
( 
4.1 
 
none n/d 4.7 
 
none n/d 
4.2 
 
none n/d 4.8 
 
none n/d 
4.3 
 
10 177 4.9 
 
12 162 
4.4 
 
9 337 4.10 
 
10 155 
4.5 
 
none n/d 4.11 
 
10 393 
4.6 
 
none n/d 4.12 
 
12 35.4 
         
C6-, C7- and C8- chloro substituted 4.13-4.15 had MICs 5-6 times more active than the 
5-chloro 4.16 or unsubstituted benzenoid 4.3 (Table 4.2). The 8-methyl 4.17, the 5-
methoxy 4.24 and the 6-methoxy 4.23 were less active than the original unsubstituted 
benzenoid compound.  
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Table 4.2: SAR of benzenoid substitutions 
        
Compound Structure ZOI 
(mm) 
MIC 
( 
Compound Structure ZOI 
(mm) 
MIC 
( 
4.3 
 
10 177 4.19 
 
none n/d 
4.13 
 
10 31.6 4.20 
 
none n/d 
4.14 
 
12 31.6 4.21 
 
none n/d 
4.15 
 
11 31.6 4.22 
 
none n/d 
4.16 
 
9 158 4.23 
 
10 240 
4.17 
 
10 337 4.24 
 
9 320 
4.18 
 
none n/d     
         
The two lone active non-aromatic 2,4-diaminoquinazolines displayed quite different 
MICs. The N
2
-cyclopentyl-N
4
-isopropyl 4.32 had an MIC comparable to the N
4
-furfuryl- 
N
2
-cycloalkyl 4.9 and 4.10 or N
4
-furfuryl-N
2
-isopropyl 4.3. Compound 4.38, N
4
-
cyclohexyl-N
2
-isopropylquinazolin-2,4-diamine with an MIC of 3.5 µM, was the only 
analogue of the entire series displaying single digit micromolar activity. This lone highly 
active dialkyl 2,4-diaminoquinazoline makes for an interesting point in the table. 
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Table 4.3: N
2
- and N
4
-substitutions rich in sp
3
 hybridized carbons 
        
Compound Structure 
ZOI 
(mm) 
MIC 
( Compound Structure 
ZOI 
(mm) 
MIC 
( 
4.25 
 
none n/d 4.33 
 
none n/d 
4.26 
 
none n/d 4.34 
 
none n/d 
4.27 
 
none n/d 4.35 
 
none n/d 
4.28  
 
none n/d 4.36 
 
none n/d 
4.29 
 
none n/d 4.37 
 
none n/d 
4.30 
 
none n/d 4.38 
 
13 3.52 
4.31 
 
none n/d 4.39 
 
none n/d 
4.32 
 
8 185 4.40 
 
none n/d 
         
N
2
-benzyl substituted 4.41 and 4.42 mimic the N
2
-furfuryl substituted quinazolines 4.11 
and 4.12 (Table 4.4). N
4
-benzyl 4.47 displays a better activity than N
4
-furfuryl 4.53, 
however, with respective MICs of 5.9 and 30 . Phenyl and benzyl substituted 4.48-
4.50 have a wide range of MICs, from 30 to 1300 . N-butyl derivatives of N-benzyl 
4.43 and 4.45 and N-phenyl 4.44 and 4.46 have MICs ranging from 6.5 to 160  with 
N
4
-benzyl-N
2
-butyl 4.45 having an MIC of 6.5 .  
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Table 4.4: N
2
- and/or N
4
-benzyl and/or phenyl substitutions 
        
Compound Structure 
ZOI 
(mm) 
MIC 
( Compound Structure 
ZOI 
(mm) 
MIC 
( 
4.41 
 
11 189 4.48 
 
10 32.0 
4.42 
 
13 34 4.49 
 
10 1300 
4.43 
 
12 163 4.50 
 
10 30.6 
4.44 
 
12 34.2 4.51 
 
10 28.5 
4.45 
 
12 6.53 4.52 
 
10 28.5 
4.46 
 
14 34.2 4.53 
 
11 30.3 
4.47 
 
13 5.88     
         
4.2.3 Derivatization Based on Initial SAR 
The three most active quinazolines found in the SAR were 4.38, 4.45 and 4.47. 
Compound 4.38 was the lone highly active quinazoline without an aromatic side chain. It 
was decided that analogues would not be synthesized based on mutation frequency, data 
shown later (section 4.2.7). As seen in Table 4.4, all tested compounds with aromatic side 
chains were active. Table 4.2 allowed for the determination that benzenoid chloro 
substitution could increase the activity of new derivatives. Thus, analogues were 
synthesized by combining the benzenoid 7-chloro group with a variety of N
2
- and N
4
-
benzyl substitutions and also by using para substituted benzyl amines.  
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In comparison to reference compounds 4.45 and 4.47, 7-chloro-quinazolines 4.54 and 
4.55 displayed slightly reduced MICs (Table 4.5).  
Table 4.5: Combination with 7-chloro or p-substituted benzyl at N
2
 and/or N
4
  
      
Compound Structure 
MIC 
( Compound Structure 
MIC 
( 
4.45 
 
6.53 4.59 
 
5.64 
4.47 
 
5.88 4.60 
 
70.5 
4.54 
 
5.34 4.61 
 
5.43 
4.55 
 
2.93 4.62 
 
5.40 
4.56 
 
5.34 4.63 
 
67.5 
4.57 
 
5.34 4.64 
 
35.0 
4.58 
 
0.61    
      
 
The para positions of the N
2
- and N
4
-benzyl moieties were considered to be ideal sites to 
introduce chloro, methyl and methoxy groups. Mono N
2
-4-chlorobenzyl 4.56, N
2
-4-
methylbenzyl 4.59 and N
2
-4-methoxybenzyl 4.62, as well as the mono N
4
-4-chlorobenzyl 
4.57, were as active as the parent 4.47. The mono N
4
-4-methylbenzyl 4.60 and N
4
-4-
methoxybenzyl 4.63 were less active than 4.47. The N
2
,N
4
-di-(4-methylbenzyl) 4.61 was 
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as active as 4.47, N
2
,N
4
-di-(4-methoxybenzyl) 4.64 was less active, and N
2
,N
4
-di-(4-
chlorobenzyl) 4.58 was nearly ten times more active with an MIC of 0.61 .  
The MIC of less than 1 µM for compound 4.58 was exciting and seen as a target to be 
improved upon. Benzenoid chloro substitution was applied without success in 
compounds 4.65 and 4.66 (Figure 4.6). A one hundred fold activity decrease from the 
dichloro 4.58 to the trichloro 4.66 was observed. The N
2
-(p-methoxybenzyl) 4.62 was 
also thought to be improved with 7-chloro substituted 4.65, but a four-fold drop in 
activity was observed. A combination 7-chloro-N
4
-(p-chlorobenzyl)-N
2
-(p-
methoxybenzyl) 4.67 was tested and displayed better activity than the trichloro 
compound, but was still not near the original activity that was hoped to be replicated. 
Table 4.6: Combination with 7-chloro and/or p-substituted benzyl at N
2
 and/or N
4
 
      
Compound Structure 
MIC 
( Compound Structure 
MIC 
( 
4.47 
 
5.88 4.65 
 
22.2 
4.54 
 
5.34 4.66 
 
67.6 
4.58 
 
0.61 4.67 
 
51.2 
4.62 
 
5.40    
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4.2.4 Determination of Minimum Bactericidal Concentration for Compounds 4.47 and 
4.58  
An important distinction of antibiotics is whether they are bactericidal or bacteriostatic. 
Bactericidal agents kill bacteria while bacteriostatic agents prevent their reproduction. 
The minimum bactericidal concentrations (MBC) were determined from MIC samples.  
The MIC samples were serial diluted and plated onto TSA plates.  The plates were then 
incubated overnight at 37°C.  MBCs were determined by calculating the CFU per mL for 
each of the concentrations of compounds tested.  The data is represented as the percent 
killing by comparing the drug containing samples to samples that contain no drug. 
Quinazoline 4.47 was not found to be bactericidal when tested up to two and a half times 
the MIC, with a percent recovery over 100% (Figure 4.3). 4.58, on the other hand, was 
found to be bactericidal with a 95% recovery at four times the MIC and a percent 
recovery of 1.0% at eight times the MIC. The MBC50 for 4.58 was 3.6 µM and was six 
times the MIC at 0.61 µM. 
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Figure 4.3: Percent recovery curves of 4.47 and 4.58  
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4.2.5 Determining the Minimum Biofilm Eradication Concentration for Compound 
4.47 
Quinazoline 4.47 was also tested to determine the minimum biofilm eradication 
concentration (MBEC). Determining the MBEC demonstrates if a compound is able to 
target cells forming biofilms, which is a common problem in healthcare settings. 
Quinazoline 4.47 was not found to eliminate biofilms when tested up to two and a half 
times the MIC, with a percent survival over 100% (Figure 4.4). 
 
Figure 4.4: Percent survival curve for 4.47 against MRSA biofilm 
The MBEC is determined based on the recovered CFU per milliliter compared to the 
control with no added compound. Briefly, S. aureus biofilms were grown in a 96-well 
plate, at 37°C for 24 hours. After this time, media was aspirated leaving a biofilm that is 
adherent to the walls of the 96-well plate, and replaced with fresh media containing 0X, 
0.2X, 0.5X, 1X, 2.5X, 5X or 10X the MIC of relevant compounds.  Samples were 
incubated at 37°C overnight, before gently being washed twice with sterile PBS, being 
careful not to disrupt the biofilm. Buffer was then removed by aspirating and biofilms 
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were disrupted by the addition of 200 μL of PBS and pipetting samples repeatedly until 
all cells were in suspension. This was then serially diluted, and plated for viable colony 
forming units. MBEC values were determined by comparison to untreated controls. 
4.2.6 Cytotoxicity and Hemolysis Assays of Selected Compounds 
The cytotoxicity of front runner compounds was determined against adenocarcinomic 
human alveolar basal epithelial cells (A549 cells, Table 4.7). Front runner compounds 
4.38, 4.45 and 4.47 had EC50s of approximately 20 µM against the A549 cells and 
selectivity indices (EC50(A549)/MIC) between 3.0 and 6.3. The designed compound 4.58 
had a selectivity index of 10 with a lower EC50 of 6.1 µM.  
Table 4.7: A549 EC50 and selectivity indices of select compounds 
Compound EC50 (M) SI (EC50/MIC) 
4.38 22.2 ± 4.2 6.3 
4.45 19.3 ± 2.6 3.0 
4.47 25.6 ± 2.1 4.4 
4.58 6.11 ± 1.47 10 
 
As another cytotoxicity test, compound 4.47 was tested in a hemolysis assay to determine 
the effect of this quinazoline against blood cells at the MIC. An optical density curve at 
540 nm shows the free hemoglobin that is released from lysed cells. Over a four hour 
period there was no significant difference between the standard solution with no 
compound and the test solution with 4.47 at the minimum inhibition concentration 
(Figure 4.5). 
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Figure 4.5: OD540 of erythrocytes in the presence or absence of 4.47 
4.2.7 Determination of Staphylococcus aureus Resistance to Quinazolines 
An important attribute of potential anti-microbials is that spontaneous resistance is not 
easily obtained. Spontaneous resistance occurs when point mutations results in the ability 
of bacteria to gain resistance to antibiotics. Thus the spontaneous mutation frequencies 
for a few of the frontrunner compounds were determined. Spontaneous mutation 
frequencies were tested for compounds 4.38, 4.45 and 4.47 by plating 1 x 10
9
 cells of S. 
aureus CBD-635 on agar containing 2.5 X the MIC of each compound. For compound 
4.38 a bacterial lawn was obtained, indicating that resistance to this compound was 
encountered quite readily. Seven spontaneous mutants were found for bis-benzyl-
substituted quinazoline 4.47 over ten replicates with a combined inoculum of 2.31 x 10
10
, 
yielding a mutation frequency of 3.03 x 10
-10
.  N
2
-butyl-N
4
-benzyl 4.45 grew no mutants 
with a combined inoculum of 2.31 x 10
10
, resulting in a mutation frequency of less than 1 
x 10
-11
. These results are very promising considering that generally a mutation frequency 
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smaller than 10
-8
 is desired for the development of anti-bacterial agents. The seven 
mutants formed using 4.47 were then tested against compounds 4.54-4.64.  
4.47 lost all activity against the mutant strains, with MICs greater than 590 µM, 
compared with 5.9 µM against the original USA 635 (Figure 4.6). 4.54, with an original 
activity of 5.34 µM, had activity drop to 26 µM for M1 and M2 while it increased to 2.6 
µM against M3-7. Activity for 4.55 was found to be 2.93 µM against the mutants and 
original strain alike. Activity was reduced from 5.34 µM to 26 µM against M1 for 4.56, 
while the activity against M2-M7 was increased to 2.6 µM. 4.57 saw the activity increase 
from 5.34 µM to 2.6 µM against all seven mutants. 4.58 was only tested against M1 and 
M2, and had activity drop from 0.61 µM to 24 µM. 4.59, with an original activity of 5.64 
µM, had activity drop to 28 µM for M1 while it increased to 2.8 µM against M2-7. 
Activity was reduced from 5.43 µM to 27 µM against M1 and M2 for 4.61, while the 
activity against M3-M7 was increased to 2.7 µM. 4.62 had activity jump from 5.40 µM to 
27 µM against M1-3 and to 270 µM against M4, while the activity increased to 2.7 µM in 
M5-M7. In all mutant strains, 4.64 had a reduction of activity from 35 µM against the 
original strain. Against strains M5 and M6 the activity was 125 µM and for the rest of the 
strains it was greater than 250 µM. Compounds 4.60 (original MIC 70.5 ) and 4.63 
(original MIC 67.5 ) were found to be more active against the mutants than the 
original strain. Against M1 and M2 4.60 had MICs of 2.8 µM whereas the MIC for M3-7 
was 28 µM. 4.63 had MICs of 2.7 µM in M4 and M6 and 27 µM in the rest of the 
mutants. This data shows that although mutants are formed, they do not have broad 
spectrum resistance to the class of quinazolines. 
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Figure 4.6: MICs of selected compounds of against the seven mutants formed from 4.47 
4.2.8 Exploring the Mechanism of Action for 4.45 
DNA sequence analysis of the mutants formed from quinazoline analogue 4.45 was 
employed to determine if a common mechanism of action could be determined from the 
mechanism of resistance. The Quinolone Resistance-Determining Regions (QRDR) for 
the genes encoding DNA gyrase (gyrA and gyrB) and topoisomerase IV (grlA and grlB) 
were sequenced for the mutants and determined to be identical to the parent strain, using 
the method reported previously by Horri et al.
143
 As quinazolines have been shown to be 
inhibitors of dihydrofolate reductase (DHFR), sequencing analysis of the gene coding for 
this enzyme was also undertaken.
144
 Again, the mutant strain was found to be identical to 
the parent strain. These results allow for the conclusion that the mechanism of resistance 
for the few mutant strains was not via a change in primary enzyme structure. 
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4.2.9 Galleria mellonella Larval Model 
Galleria mellonella larvae, also known as the wax moth, were used as an initial in vivo 
model to determine efficacy of front runner compounds 4.38, 4.45, 4.47 and 4.58 (Figure 
4.6). Uninfected larvae were injected with DMSO to determine the effect of the injection 
solvent. Larvae were infected by injection with between 1.78 x 10
9
 and 4.63 x 10
9
 colony 
forming units (CFUs) of S. aureus USA 300 FPR strain. One hour post-infection 5x or 
10x the MIC for each compound was injected, or the larvae were left untreated.  
30% of uninfected larvae died within twenty-four hours post DMSO injection while the 
remaining 70% lived to day three (p = 0.057), p values were calculated using Graph pad. 
 Mortality was measured using a log rank and chi-square test with 1 degree of freedom. 
 The significance level was set at 0.05. All untreated infected larvae were dead within 
forty-eight hours following infection. Compound 4.38 was tested at two inoculations, 
2.89 x 10
9
 and 4.63 x 10
9
 CFUs (Figure 4.7). Within the first twenty-four hours, 50% and 
20% of larvae died after doses of 4.38 of 5x and 10x the MIC, respectively, with 40% 
from each surviving after day two from 2.89 x 10
9
 CFUs. For 4.63 x 10
9
 CFUs, 40% died 
within twenty-four hours with 10% additional dying every twenty-four hours until day 
three at a dose of 5x the MIC (p = 0.0526). At 10x the MIC, 30% died within twenty-four 
hours and the remaining 70% survived until day three (p = 0.157).  
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Figure 4.7: Wax worm larvae survival post-infection for 4.38 with low and high 
inoculation volumes. Low and high refer to the inoculation volumes discussed earlier in 
the text. * = p < 0.05 
 
Quinazoline 4.45 was tested at two inoculations, 2.89 x 10
9
 and 4.63 x 10
9
 CFUs (Figure 
4.8). In the 5x MIC test at 2.89 x 10
9
 CFUs, 50% of larvae died within twenty-four hours 
and 40% survived past day two (p = 0.156). 30% of larvae died within twenty-four hours 
and the rest survived until day three in the 10x MIC test (p = 0.0268). For 4.63 x 10
9
 
CFUs, 80% died within twenty-four hours with 10% additional dying before day three at 
5x the MIC (p = 0.156). At 10x the MIC, 40% died the first day, 10% the second and 
30% the third (p = 0.0268).  
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Figure 4.8: Wax worm larvae survival post-infection for 4.45 with low and high 
inoculation volumes. Low and high refer to the inoculation volumes discussed earlier in 
the text. * = p < 0.05 
 
Compound 4.47 was tested at 1.78 x 10
9
 CFUs (Figure 4.9). In the 5x MIC test, 10% of 
larva died within twenty-four hours and an additional 40% died in the next twenty-four 
hours, leaving 50% alive at day three (p = 0.0035). In contrast, 30% of larvae died within 
twenty-four hours and an additional 40% died in the next twenty-four hours, leaving 30% 
alive at day three in the 10x MIC test (p = 0.0573). 
Compound 4.58 was tested at 2.89 x 10
9
 CFUs (Figure 4.9). In the 5x MIC assay, 50% of 
larvae died within twenty-four hours and the remaining 50% survived until day three (p = 
0.0779). 30% of larvae died within twenty-four hours and an additional 10% died in the 
next twenty-four hours, leaving 60% alive at day three in the 10x MIC test (p = 0.0147).  
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Figure 4.9: Wax worm larvae survival post-infection for 4.47 and 4.58. * = p < 0.05 
4.2.10 In vivo Efficacy Using a Murine Model of Lethal Peritonitis 
The efficacy of compounds 4.45 and 4.47 were determined in a murine model of lethal S. 
aureus peritonitis (Figure 4.10). Groups of six female 6 week old CD1 mice were 
injected intraperitoneally with 1 x 10
8
 CFUs of S. aureus USA 300. After one hour the 
groups of mice were given intravenous injections with either 45% w/v (2-
hydroxypropyl)--cyclodextrin (HPCD) in water, 5 mg/kg or 10 mg/kg of vancomycin, 
5x the MIC of 4.45 in 45% w/v HPCD in water and 1x, 5x, or 10x the MIC of 4.47 in 
45% w/v HPCD in water. At 5 mg of vancomycin, three mice died after the first day 
and the rest survived to the end of the week (p = 0.264). At 10 mg of vancomycin, one 
mouse died after the first day and the rest survived to the end of the week (p = 0.027). For 
compound 4.45, one mouse died immediately following the 5x MIC injection and the 
other five survived to the end of the test at day 5 (p = 0.352). For compound 4.47, all six 
mice survived 5 days at 1x the MIC (p = 0.0058) while one mouse died immediately 
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following the 5x injection (p = 0.0589) and five died immediately following the 10x 
injection. With injection of 45% w/v HPCD in water all six mice were dead by day 
three (p = 0.53). 
 
Figure 4.10: Mice survival post-infection. * = p < 0.05 
4.2.11 Conclusions 
A total of 67 N
2
,N
4
-disubstituted quinazoline-2,4-diamines, many displaying anti-
bacterial activities, have been synthesized systematically by varying the substitutions in 
the 2-, 4-, 5-, 6-, 7-, and/or 8-positions. The most potent in vitro activities with MICs in 
the single digit to sub-micromolar range against S. aureus were obtained with 
quinazoline-2,4-diamines 4.38, 4.45, 4.47, 4.54-4.59 and 4.61-4.62 bearing a N
4
-
cyclohexyl-N
2
-isopropyl or N
4
-benzyl and either N
2
-benzyl or N
2
-n-butyl substituent 
combination. Furthermore, the benzenoid ring of the quinazoline-2,4-diamine scaffold 
has been identified to play a secondary role for efficacy, with quinazolines substituted at 
the 6-, 7- or 8-position with one chloro group possessing lower MICs against S. aureus. 
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These promising results led to efficacy testing of the lead compounds 4.38, 4.45, 4.47 and 
4.58 in an in vivo wax moth larva S. aureus model and compounds 4.45 and 4.47 in an in 
vivo murine S. aureus model.  
All compounds fared better in the wax moth larva study than the untreated versions. On 
average, out of ten, 3.83 larvae treated with 5x the MIC survived to the end of the study 
while 4.83 treated with 10x the MIC survived. This results in a 55% and 69% respective 
survival rate when compared to the DMSO standard.  
In the murine model, all treated mice also fared better than the untreated versions. 1x the 
MIC for compound 4.47 gave the best results with all mice surviving to the end of the 
one week study. 5x the MIC for both compounds 4.45 and 4.47 had five of six mice 
survive to the end of the week, giving the next best results and the same as 10 mg/kg of 
vancomycin. 10x the MIC for compound 4.47 resulted in the immediate death of five of 
the six mice. Additional experiments are required to determine whether these deaths have 
been caused due to toxicity or limited solubility during administration of compounds 4.45 
and 4.47. 
The observed potencies of frontrunner compounds 4.38, 4.45, 4.47 and 4.58 in in vivo 
assays make N
2
,N
4
-disubstituted quinazoline-2,4-diamines a suitable platform for the 
future development of anti-bacterial agents, with a strong focus being on methicillin-
resistant Staphylococcus aureus. 
4.3 Screening of Quinazolines Against ESKAPE Pathogens 
With the activity of the quinazoline class of compounds against MRSA, we decided to 
test the library of quinazolines against the rest of the ESKAPE pathogens (Enterococcus 
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faecium, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacter species) in a high-throughput screen. Testing of 67 quinazolines was 
performed with the remaining pathogens (e.g. not MRSA) using MIC assays as described 
above. We determined that compound 4.41 from this class was active against A. 
baumannii with an MIC of 18.9 µM. The rest of the compounds had MICs >56 µM and 
all were inactive to the rest of the ESKAPE pathogens.  
4.3.1 Structure-Activity Relationship of Quinazolin-2,4-diamines by Minimum 
Inhibitory Concentration 
As compound 4.41 was the only active compound, derivatives of this quinazoline were 
tested. N
4
-isopropyl derivative 4.42 and the N
4
-n-butyl 4.43 were inactive, showing that 
small alkyl substituents other than methyl are not active. Thus, a variety of N-benzyl-N-
methylquinazolin-2,4-diamines were synthesized and tested (Table 4.8).  
Table 4.8: MICs of N-benzyl-N-methylquinazolin-2,4-diamines against A. baumannii 
1403 strain 
      
   
 
Structure 
MIC 
(M 
 Structure 
MIC 
(M 
 Structure 
MIC 
(M 
4.41 
 
18.9 
4.69 
 
33.5 
4.71 
 
3.40 
4.68 
 
18.9 
4.70 
 
1.67 
   
          
The N
4
-benzyl-N
2
-methyl derivative 4.68 displayed the same activity as 4.41, showing 
that N-benzyl-N-methyl derivation leads to activity against A. baumannii. The N
2
-n-butyl 
4.45 was also inactive in the original assay. Backbone substituted derivatives of 4.41, 
however, were found to be active. 7-chloro derivative 4.69 had activity reduced nearly 
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two-fold, while 6-derivation to methoxy 4.71 and chloro 4.70 increased the activity 
greater than five-and-a-half- and eleven-fold, respectively. 
4.3.2 Extended Minimum Inhibitory Concentration Testing 
After the initial tests against A. baumanni strain 1403, the active compounds 4.41 and 
4.68-4.71 and some similar analogues (4.1, 4.11, 4.14, 4.15 and 4.43) were tested for 
MICs against other drug resistant strains of A. baumannii to determine if activity was 
shown across a wide range of isolates (Table 4.9). A. baumanni strains A-L were 
provided courtesy of Paul Dunman from the University of Rochester Medical Center. The 
five original hits 4.41 and 4.68-4.71 were active against the majority of the additional 
strains. The 6- and 7-substituted derivatives 4.69-4.71 were active against all thirteen 
strains with MICs below 34 µM. Compound 4.71 displayed the best across the board 
activity with MICs of 3.4 µM for all strains except against K and L, with MICs of 17 µM. 
Three of the compounds (4.11, 4.42 and 4.43) that were inactive against the 1403 strain 
were active against at least one of the other twelve strains. Compound 4.11  was active 
against the A and B strains with MICs of 39 µM, 4.42 was active against the B strain 
with an MIC of 34 µM and 4.43 was active against A, B and D strains with MICs of 3.3 
µM, 3.3 µM and 33 µM, respectively. 
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Table 4.9: MICs of active compounds and similar compounds against A. baumanni 1403 
and A-L strains 
 
Structure 
MIC (M 
 
            
 
 1403 A B C D E F G H I J K L 
4.1 
 
>98 >98 >98 >98 >98 >98 >98 >98 >98 >98 >98 >98 >98 
4.11 
 
>98 39 39 >98 >98 >98 >98 >98 >98 >98 >98 >98 >98 
4.14 
 
>79 >79 >79 >79 >79 >79 >79 >79 >79 >79 >79 >79 >79 
4.15 
 
>79 >79 >79 >79 >79 >79 >79 >79 >79 >79 >79 >79 >79 
4.41 
 
18.9 19 38 3.8 38 38 38 38 38 3.8 95 >95 >95 
4.42 
 
>86 >86 34 >86 >86 >86 >86 >86 >86 >86 >86 >86 >86 
4.43 
 
>82 3.3 3.3 >82 33 >82 >82 >82 >82 >82 >82 >82 >82 
4.68 
 
18.9 38 3.8 3.8 95 >95 95 95 38 95 >95 95 95 
4.69 
 
33.5 6.7 6.7 6.7 3.4 6.7 6.7 5.0 30 6.7 6.7 6.7 3.4 
4.70 
 
1.67 17 17 8.4 0.3 8.4 8.4 3.3 17 8.4 17 34 8.4 
4.71 
 
3.40 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 17 17 
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4.3.3 Minimum Bactericidal Concentrations Activity of Frontrunner Quinazolin-2,4-
Diamines Against Acinetobacter baumannii   
MBC testing of 4.41, 4.42, 4.68, 4.70 and 4.71 was performed to determine whether the 
compounds were bactericidal or bacteriostatic against A. baumannii 1403 (Figure 4.11). 
All tested compounds reduced the percent recovery of cells as the concentration increased 
and were thus found to be bactericidal, including compound 4.42 which was completely 
inactive against A. baumannii 1403 when the MIC was tested.  
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Figure 4.11: Percent recovery curves for A. baumannii 1403 incubated with quinazolines 
For 4.41, we observed 0.06% recovery of cells at the MIC of 18.9 µM with an MBC50 
value of 3.6 µM and a MBC90 value of 4.3 µM. For 4.42, we observed <6% recovery of 
cells at the MIC of >86 µM with an MBC50 value of 2.5 µM and a MBC90 value of 40 
µM. For 4.68, we observed 12.67% recovery of cells at the MIC of 18.9 µM with an 
MBC50 value of 2.2 µM and a MBC90 value of 5.0 µM. For 4.70, we observed 30% 
recovery of cells at the MIC of 1.57 µM with an MBC50 value of 0.85 µM and a MBC90 
value of 5.9 µM. Finally, for 4.71, we observed 6.8% recovery of cells at the MIC of 3.40 
µM and an MBC50 value of 1.8 µM and a MBC90 value of 9.1 µM. These demonstrate 
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that all of the tested N-benzyl-N-methyl-2,4-diaminoquinazolines are broadly bactericidal 
in action towards A. baumannii with the MBC50 values for all compounds less than their 
MIC.   
4.3.4 Determining the Minimum Biofilm Eradication Concentration for 4.41 and 4.68-
4.71 
As biofilm formation by A. baumannii is a factor that increases pathogenicity and innate 
antibiotic resistance, the active quinazolines 4.41 and 4.68-4.71 were tested for their 
capacity to destroy biofilms. Briefly, A. baumannii biofilms were grown in a 96-well 
plate, at 37°C for 24 hours. After this time, media was aspirated leaving a biofilm that is 
adherent to the walls of the 96-well plate, and replaced with fresh media containing 0X, 
0.2X, 0.5X, 1X, 2.5X, 5X or 10X the MIC of relevant compounds.  Samples were 
incubated at 37°C overnight, before gently being washed twice with sterile PBS, being 
careful not to disrupt the biofilm. Buffer was then removed by aspirating and biofilms 
were disrupted by the addition of 200 μL of PBS and pipetting samples repeatedly until 
all cells were in suspension. This was then serially diluted, and plated for viable colony 
forming units. MBEC values were determined by comparison to untreated controls. 
Compounds 4.41, 4.68, 4.69 and 4.71 were completely ineffective against biofilms at all 
tested concentrations, with greater than 100% recovery of cells at all tested 
concentrations. Quinazoline 4.70, however, showed the ability to eradicate cells within 
biofilms. At the MIC of 1.67 µM, 46.2% of the cells from the original culture were 
recovered while 38.5% of the cells were recovered at the lowest tested concentration 
(0.2X the MIC) of 0.33 µM and 15.4% recovery at 8.4 µM (5X the MIC). The MBEC50 
133 
 
of 0.3 µM and MBEC90 of 3.0 µM show this compound to have anti-biofilm activity at 
activities comparable to the MIC. 
 
Figure 4.12: Percent recovery curve for A. baumannii biofilm grown in the presence of 
4.70 
4.3.5 Cytotoxicity of 4.70 
The cytoxicity of 4.70 was determined against A549 cells and was found to be 16.7 ± 6.0 
µM. This gave a selectivity index of 10 when compared to the MIC, showing that this 
compound may have therapeutic use in vivo.  
4.3.6 In vivo Model of Infection Using Galleria mellonella 
The G. mellonella model was used as an initial in vivo study to test the efficacy of 
frontrunner quinazolines against A. baumannii. Ten larvae per compound were infected 
with 1.0 x 10
7
 A. baumannii. One hour post-infection, 5x the MIC of each compound or 
the DMSO vehicle was administered to the worms. An additional group of uninfected 
larvae was tested for survivability with DMSO. All infected worms subjected to 
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treatment with DMSO were dead within two days, while 80% of the uninfected worms 
survived to day 3 (p = 0.0012, Figure 4.10).  
Compound 4.41 had 50% of worms survive past the first day (p = 0.0056), while 
compound 4.69 had 40% survive (p = 0.214). Compounds 4.68, 4.70 and 4.71 resulted in 
70% surviving until day three, with compound 4.68 having 10% die after the first day and 
20% after the second (p = 0.0003), while 4.70 (p = 0.0061) and 4.71 (p = 0.002) had all 
30% die after the first day. 
 
Figure 4.13: Wax worm larvae survival post-infection with 5x MIC. * = p < 0.05 
A murine model of infection is currently being studied to determine the efficacy of these 
compounds in mammalian systems. 
4.3.7 Conclusions 
Testing of the 67 quinazolines in an in vitro model of A. baumannii infection revealed 
one compound 4.41 that displayed activity, a surprisingly low number when compared to 
the activity of these agents with MRSA. Screening of analogues of 4.41 revealed five 
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quinazolines that were broadly effective against thirteen strains of A. baumannii, with 
compound 4.71 displaying activity most consistently. While the other four compounds 
were inactive, 4.70 was also found to eradicate biofilms, showing the ability to remove 
cells that are generally impervious to antibiotics. The in vivo G. mellonella model of 
infection produced results that suggested good in vivo activity for these compounds. 
Compounds 4.68, 4.70 and 4.71 had 70% of the wax worms survive, which corresponds 
to an 87.5% cure rate when compared to the DMSO model. In summary, the N-benzyl-N-
methylquinazolin-2,4-diamines display excellent in vitro and in vivo efficacy for A. 
baumannii treatment as bactericidal agents. This data strongly suggests that these 
compounds should be studied further as anti-bacterials. 
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Chapter 5: Future Plans 
5.1 1,4-Dihydropyridines 
5.1.1 Synthesis Going Forward 
Analysis of the structure-activity relationship revealed logical compounds to be 
synthesized for the further optimization of activity. At the 4- and 7- positions, the use of 
unsubstituted phenyl derivatives will allow for the determination of whether or not 
substitution is necessary.  Derivatives with a 7-O that were highly active, such as 2.31, 
2.32, 2.52 and 2.53, will be synthesized as well to see if a corresponding increase in 
activity is encountered with the 7-CH2 derivative.  
SAR of the 3-position revealed that a smaller alkyl chain has the best activity. Since an 
ethyl group was the smallest derivative formed, two new sets will be tested, one with a 
methyl ester and the second with the free acid to determine if a smaller ester or the free 
acid can be as active as the ethyl ester.  
5.1.2 Property-Based Synthesis 
Determination of the solubility properties of the pure stereoisomers of 2.1 showed that 
the compounds have low aqueous solubilities. A higher aqueous solubility is desirable for 
potential therapeutic use and oral bioavailability. As discussed previously, the free acid at 
the 3-position will be synthesized. If this molecule retains in vitro activity it should have 
an increased solubility compared to an ester derivative.  
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The 2-position appears to be an excellent place to attempt modifications based on 
properties as derivatives with larger groups have been more active than a simple methyl 
group. Determination of the solubilities of oxygen containing derivatives 2.53 and 2.54 
may reveal compounds that already have desirable solubilities in place. The solubilites of 
compounds 2.1 and 2.2 will also be compared to determine how much of an effect on 
solubility the 6-O has on the molecule. As well as these compounds, derivatives can be 
synthesized with functional groups that are well known for increasing solubility such as 
morpholine. Synthesis of these derivatives can be undertaken from the 1,4-
dihydrohypyridine by halogenation at the 2-position followed by substitution with a 
proper group (Figure 5.1). Derivatives will also be tested baring heteroaryl functionality 
at the 4- and 7- positions to see the effects of different aromatic systems, such as pyridyl. 
 
Figure 5.1: Derivation at the 2-position 
5.1.3 Additional Testing 
Additional property testing should be performed to determine the potential for these 
compounds to be successful therapeutic treatments. Pharmacokinetics (PK) and 
pharmacodynamics (PD) are important to study because they are used to decipher what 
the body does to a compound (PK) and what a compound does to the body (PD). 
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Common PK tests are the ADME properties: absorption, distribution, metabolism and 
excretion. These properties are used to determine how well a compound acts in the body 
and are an excellent description of the potential a compound has for in vivo testing. 
Microsomal testing should be performed to see how the compounds can be metabolized 
in the body. Identifying sites of oxidation or bond cleavage will allow for modifications 
to the structure that will provide for a longer active effect for the compound in the body, 
preventing the excretion of a metabolized compound from a body. Oftentimes aryl rings 
can be oxidized to phenols by an enzyme and the specific sites can be blocked by 
replacing a hydrogen atom with a fluorine with minimal change in activity. Esters and 
ethers can often times be cleaved, and if this can be identified early on the functional 
groups can be changed, such as replacing the methoxy groups on the 7-phenyl. 
Identification of more highly soluble compounds and compounds displaying good PK 
properties will lead to compounds that will be valuable as in vivo leads. A murine model 
of infection for P. falciparum has been found to be an effective test for initial studies. If 
this test leads to good results then further in vivo tests will be performed in a primate 
model to determine whether the 1,4-dihydropyridines will make a good platform for 
clinical studies. 
5.1.4 Stereoselective Syntheses 
The stereoselective synthesis of the 1,4-dihydropyridines can be studied as well. The 
trans isomer is generally formed in a slight excess due to steric hindrance between the 4- 
and 7- positions, and varying substituents can be tested to see their effect on the ratio. 
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Bulkier substituents would reveal whether it is strictly a steric observation while using 
strongly electronegative atoms would reveal whether an electronic repulsion is observed.  
A revisit of a few stereoselective processes will also occur. Chiral lactone synthesis will 
be attempted again, with the replacement of the benzyl proton with a methyl group with 
the hopes of isolating enantiopure compounds. The α-β unsaturated lactone may also try 
to be resynthesized, as there was a noted difference in ee when pyridine was used as the 
base instead of triethylamine. It may be that a suitable base can be found to increase the 
ee into the upper ninety percent. 
Enantioselective syntheses of the 1,4-dihydropyridine is another method that will be 
reevaluated. A chiral hydrazine could be used to set the stereochemistry via the nitrogen 
of the pyridine ring. As Enders et al. performed stereoselective syntheses with one 
stereocenter, their method may be applied to a series with a second stereocenter.
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Several conditions will be used to see the effects that solvent and temperature have on the 
reaction.  
5.2 Quinazolines as Anti-Leishmanials 
As limited success has been found with the quinazolin-2,4-diamines in in vivo murine 
models, studies need to be conducted on the properties of these compounds to determine 
if better efficacy can be attained by the synthesis of compounds with more favorable 
properties. The microsomal stability should be studied especially since the furan 
substituent is a moiety that is well known at being metabolized. Isosteres may need to be 
synthesized that keep the biological activity but prevent degradation and increase 
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solubility as the active compounds without a furan are generally more hydrophobic with 
less favorable aqueous solubility. 
5.3 Quinazolines as Antibacterials 
As a large number of compounds have been tested, a qualitative structure-activity 
relationship (QSAR) study may be appropriate to have a computational method to show 
compounds that would have better in vitro activity. QSAR may be able to explain the 
lack of highly active compounds bearing dialkyl amine substitutions and shed light on the 
more active aryl substituted compounds. 
The most active 2,4-diaminoquinazolines in the MRSA assay bore benzyl substituted 
amines. These compounds are highly lipophilic and do not have a high aqueous 
solubility. Increasing the aqueous solubility should be a priority; derivatives can be made 
with more soluble substituents such as hydroxyl or carboxyl substituted benzyl groups. 
Pyridyl substitution may also serve to increase the aqueous solubility. 
In vivo testing of the lead quinazolines revealed that protection was provided in both a 
murine model of infection and a wax worm model of infection. The murine model 
followed the test subjects for one week, while the wax worm model observed for three 
days. An extended study may provide more data via the observation of whether the 
protection will last for a longer period of time. The addition of test compound may be 
changed to a time further out than one hour post infection, allowing for the infection to 
proceed throughout the animal prior to therapy.  
As compound 4.58 was found to be bactericidal at eight times the MIC and was also the 
most active quinazoline in vitro, a murine model with this compound should be 
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undertaken to determine the efficacy of this compound. Since it is bactericidal, it may 
provide more protection than the previously tested quinazolines in vivo. 
The only active compounds in the A. baumannii test bore N-benzyl and N-methyl 
substitution. The solubility of these compounds are higher than that of the dibenzyl 
derivatives in the MRSA study, but there is room for improvement. Aqueous solubility 
could be improved via functionality on the benzyl substituent, with testing of the in vitro 
properties showing whether the analogues retain activity. 
The bactericidal and anti-biofilm activities of the active quinazolin-2,4-diamines reveal a 
strong potential for these compounds. A murine model of infection will provide data as to 
whether these compounds have potential efficacy in mammals. To go along with these in 
vivo tests, PK tests and microsomal stability can help to determine how effective they can 
be in vivo. Compound 4.41 (3.15) was tested previously in a murine model of infection 
and found to be inactive against L. donovani. The PK and microsomal stability tests can 
determine whether the lack of activity is due to the body rendering the compounds 
inactive. 
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